Jeffrey N. Myers, M.D., Ph.D., F.A.C.S.
Department of Head and Neck Surgery, Division of Surgery
About Dr. Jeffrey N. Myers
Dr. Jeffrey N. Myers received his medical (MD) and doctoral (PhD) degrees from the University of Pennsylvania School of Medicine and he then completed his residency training in Otolaryngology-Head and Neck Surgery at the University of Pittsburgh. He subsequently completed fellowship training in Head and Neck Surgical Oncology at the University of Texas MD Anderson Cancer Center, where he has been on the faculty ever since. Dr. Myers leads a basic and translational research program and his primary research interests are in the role of p53 mutation in oral cancer progression, metastasis and response to treatment.
Read More
Present Title & Affiliation
Primary Appointment
Department Chair, Department of Head and Neck Surgery, Division of Surgery, UT MD Anderson Cancer Center, Houston, TX
Endowed Distinguished Chair Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Head and Neck Surgery, Baylor College of Medicine, Houston, TX
Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
Associate Professor, Department of Head and Neck Surgery, Baylor College of Medicine, Houston, TX
Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Squamous cell carcinoma
Tongue neoplasms
p53 Gain of Function Mutations
Education & Training
Degree-Granting Education
| 1991 | University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, US, MD |
| 1991 | University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, US, School of Medicine, Biochemistry, Ph.D |
| 1983 | University of Pennsylvania, Philadelphia, Pennsylvania, US, Biochemistry, BA |
Postgraduate Training
| 1996-1997 | Fellowship, Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1992-1996 | Residency, Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania |
| 1991-1992 | Surgical Internship, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 1999 | Texas |
| 1998 | Commonwealth of Pennsylvania |
| 1997 | American Board of Otolaryngology |
Experience & Service
Faculty Academic Appointments
Hubert L. and Olive Stringer Distinguished Professorship in Cancer Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2016
Ashbel Smith Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2010
Associate Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2006
Associate Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2006
Assistant Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2002
Assistant Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2002
Administrative Appointments/Responsibilities
Department Chair, Department of Head and Neck Surgery, UT MD Anderson Cancer Center, Houston, TX, 2017 - Present
Director of translational Research, Department of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2021
Director of Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2020
Deputy Chair for Academic Programs, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2017
Director of Clinical Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2006
Fellowship Program Director, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2006
Other Professional Positions
External Reviewer, Otolaryngology Head and Neck Surgery, University Health Network, Tornoto, 2024
Co-Lead, HNS Service Line, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Leadership Institution - Leading Teams Core Curriculum, UT MD Anderson Cancer Center, Houston, TX, 2019 - 2021
Leadership Institute - Leading People Leadership: Unconscious Bias & Behavioral Interviewing, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019
Affiliate Professor, University of Copenhagen, Copenhagen, 2017 - 2022
Affiliate Professor of Otorhinolaryngology, The University of Copenhagen, Copenhagen, 2017 - Present
Member, MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2017 - Present
Member, External Advisory Board, UC San Diego Moores Cancer Center, San Diego, CA, 2015 - Present
Department of Translational Molecular Pathology Mentorship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Physician Scientist Workforce Committee, National Institutes of Health, Bethesda, MD, 2013 - 2015
Ad Hoc Member, National Institute of Health Physician-Scientist Workforce (PSW), Bethesda, MD, 2013 - Present
Member, The University of Miami Leonard M. Miller School of Medicine SPORE in Head and Neck Cancer, Houston, TX, 2013 - 2016
Member, Scientific Advisory Committee, University of Pittsburgh, Department of Otolaryngology, Pittsburgh, PA, 2012 - Present
Member, Scientific External Advisory Board, University of Michigan Head and Neck Cancer SPORE, Houston, TX, 2012 - 2016
Member, Internal Advisory Board, The Ohio State University Cancer Center/MD Anderson Cancer Center (OSU/MDACC) Thyroid Cancer SPORE, Houston, TX, 2012 - 2020
Voluntary Faculty, Baylor College of Medicine - Department of Otolaryngology-Head and Neck Surgery, Houston, TX, 2006 - 2011
Intramural Institutional Committee Activities
Reviewer, UTMDACC Harter Prize, The University of Texas MD Anderson Cancer Center, 2025 - Present
member, CCSG External Advisory Board, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, ARTNet Steering Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Allison Institute Advisory Council, The University of Texas MD Anderson Cancer Center, 2022 - Present
Chair, Community of Chairs, Executive Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Extramural Institutional Committee Activities
Program Lead, Downstream Capacity Management Program, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Space Policy Revisions Advisory Group, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, U54 Partnership for Excellence in Cancer Research Grant - Internal Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Department of Plastic Surgery Search Committee, The University of Texas MD Anderson Cancer Center, 2023
Internal Reviewer, UTMDACC Harter Prize, The University of Texas MD Anderson Cancer Center, 2023
Member, Dr. Pisters' Rounding Infrastructure Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Panelist, Rolling Strategic Plan Review, The University of Texas MD Anderson Cancer Center, 2021
Member, PRS Faculty Compensation & Benefit Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Head and Neck Stiefel Fund Steering Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Anesthesiology, Critical Care, and Pain Medicine Division Head Search Committee, The University of Texas MD Anderson Cancer Center, 2021
Chair, Division of Surgery Committee on Diversity, Equity, and Inclusion, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, COVID-19 Core Leadership Team (CCLT), The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Research Enablement, Activities and Conduct Team (REACT), The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Breakthroughs Advisory Council, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Leadership Development Council Monthly Meeting, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Care Team Transformation Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Cancer Network Strategy Executive Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Interventional Radiology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2020
Member, Strategic Position Management Committee for Research and Education Faculty, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Community of Chairs, Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2025
Member, President's Advisory Council, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Research COVID-19 Core Leadership Team (R-CCLT), The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Division of Surgery Committee on Diversity, Equity, and Inclusion, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Member, Diversity Council, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Member, Community of Chairs, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Breast SPORE - Internal Advisory Board Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2017
Co-Chair, Biorepository Governance Advisory Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2020
Member, Igniting Change Across Research (iCAR), The University of Texas MD Anderson Cancer Center, 2016 - 2020
Member, FY17 Tech Task Force Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2020
Member, Breast Surgical Oncology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Member, Division of Surgery Executive Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Physician Scientist Task Force, The University of Texas MD Anderson Cancer Center, 2014 - Present
Chairman, Head And Neck Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Internal Advisory Board, Gynecologic Oncology T32 SPORE Advisory Board, The University of Texas MD Anderson Cancer Center, 2014 - 2018
Member, Head and Neck Retreat Executive Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Member, Head and Neck Stiefel Fund Steering Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, The Vice Provost - Clinical Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2018
Chair, Search Committee, Associate Professor Tenure Track, Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 2013 - 2014
Chair, Search Committee, Assistant Professor Tenure Track for Translational Research, Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, 2013 - 2013
Member, Bridge Funding Advisory Panel, The University of Texas MD Anderson Cancer Center, 2013 - 2020
Administrator, Head and Neck SPORE, The University of Texas MD Anderson Cancer Center, 2012 - 2015
Member, Search Committee for Chair, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2012 - 2012
Member, The Vice Provost’s Advisory Council on Clinical Research, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy Education Program, Oversight Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2020
Member, Research Laboratory Space Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2016
Member, The Ohio State University Cancer Center/MD Anderson Cancer Center (OSU/MDACC) Thyroid Cancer SPORE, Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2012 - 2020
Member, Brain SPORE, Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2011 - 2021
Member, Physician-Scientist Program Oversight Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present
Member, Institutional Biospecimen Utilization Committee (iBUC), The University of Texas MD Anderson Cancer Center, 2011 - 2020
Chair, Search Committee Department of Pathology, The University of Texas MD Anderson Cancer Center, 2010 - 2012
Member, Search Committee Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Member, Search Committee for a Research Faculty Member, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2007 - 2008
Member, Scientific Publications Advisory Group, The University of Texas MD Anderson Cancer Center, 2006 - 2008
Member, Search Committee Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 2006 - 2007
Rotating Member, Research Council, The University of Texas MD Anderson Cancer Center, 2006 - 2010
Member, Promotion Tenure Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2009
Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2005 - 2008
Member, Melanoma SPORE, Internal Advisory Review Committee, The University of Texas MD Anderson Cancer Center, 2004 - Present
Member, Head and Neck SPORE Executive Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Chair, Core Curriculum Subcommittee, The University of Texas MD Anderson Cancer Center, 2001 - 2004
Member, M.D./Ph.D. Program Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2002
Member, Executive Committee, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2006
Editorial Activities
Senior Editor, Advances in Modern Oncology Research, 2017 - Present
Basic Science Reviews Section Editor, Head and Neck Journal, 2011 - 2014
Editorial Board Member, Oral Oncology, 2011 - 2014
Book Editor, Oral Cancer Metastasis, 2008 - Present
Editor/Service on Editorial Board(s), Clinical and Experimental Otorhinolaryngology, 2007 - Present
Basic Science Reviews Section Editor, Head & Neck Journal, 2007 - 2010
Section Editor, Annals of Surgical Oncology, 2004 - 2007
Editorial Board, Annals of Surgical Oncology, 2003 - 2004
Editor, Cancer, 2003 - 2007
Editorial Advisory Board, Cancer, 2003 - Present
Editor, Laryngoscope, 2002 - 2007
Editorial Board, Laryngoscope, 2002 - 2004
Book Review Editor, The American Journal of Otolaryngology, 1999 - 2000
Editorial Board, Otolaryngology-Head and Neck Surgery, International Section, 1999 - 2000
Honors & Awards
| 2022 | America's Top Doctor, Castle Connolly Medical Ltd |
| 2022 | Regional 2022 Top Doctors, American Registry |
| 2021 | Top 1% Provider on Care Experience Nationally, Consumer Assessment of Healthcare Providers and Systems |
| 2020 | 2020 Charles A LeMaistre MD Outstanding Achievement Award in Cancer, UT MD Anderson Cancer Center |
| 2019 | Presidential Citation, American Head and Neck Society (AHNS) |
| 2019 | Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2017 - 2022 | Affiliate Professor of Otorhinolaryngology, University of Copenhagen - Faculty of Health and Medical Sciences |
| 2017 - 2018 | The Best Doctors in America, Best Doctors, Inc |
| 2017 | American Association for the Advancement of Science (AAAS) Fellow |
| 2016 - 2024 | Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery, The University of Texas, MD Anderson Cancer Center |
| 2016 - 2017 | America's Top Doctors For Cancer: 2016 - 2017, Castle Connolly Medical Ltd |
| 2016 | Houston Chronicle - MedCity - Houston Top Doctors |
| 2015 | Newsweek Special Health Issue - Curing Cancer - Top Doctors, Newsweek |
| 2015 | Top Cancer Doctor for 2015, PARS International Corp |
| 2013 - 2014 | America's Top Doctors, Castle Connolly Medical Ltd, 13th Edition |
| 2013 - 2014 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd, 9th Edition |
| 2013 | Top Doctors: SE Texas, Castle Connolly Medical Ltd |
| 2012 - 2013 | America's Top Doctors, Castle Connolly Medical Ltd, 12th Edition |
| 2012 - 2013 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 8th Edition |
| 2012 | 7th Annual David Myers Distinguished Professor, University of Pennsylvania Health Systems |
| 2011 - 2014 | Texas Super Doctors |
| 2011 - 2012 | America's Top Doctors, Castle Connolly Medical Ltd, 11th Edition |
| 2011 - 2012 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 7th Edition |
| 2010 - 2014 | Hubert L. and Olive Stringer Distinguished Professorship in Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2010 - 2011 | America's Top Doctors, Castle Connolly Medical Ltd, 10th Edition |
| 2010 - 2011 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 6th Edition |
| 2009 - 2010 | America's Top Doctors, Castle Connolly Medical Ltd, 9th Edition |
| 2009 - 2010 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 5th Edition |
| 2008 - 2010 | Ashbel Smith Professorship, The University of Texas MD Anderson Cancer Center |
| 2008 - 2009 | America's Top Doctors, Castle Connolly Medical Ltd, 8th Edition |
| 2008 - 2009 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 4th Edition |
| 2008 | Top Doctors On Long Island, Newsday |
| 2007 - 2008 | America's Top Doctors, Castle Connolly Medical Ltd, 7th Edition |
| 2007 - 2008 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 3rd Edition |
| 2007 | America's Top Physicians, SLD Industries, Inc |
| 2006 - 2007 | America's Top Doctors, Castle Connolly Medical Ltd, 6th Edition |
| 2006 - 2007 | America's Top Doctors for Cancer, Castle Connolly Medical Ltd. 2nd Edition |
| 2006 | Best Boss Award, The University of Texas MD Anderson Cancer Center |
| 2006 | Houston's Top Docs |
| 2005 - 2017 | America's Top Doctors |
| 2005 - 2006 | America's Top Doctors, Castle Connolly Medical Ltd, 5th Edition |
| 2005 - 2006 | America’s Top Doctors for Cancer, Castle Connolly Medical Ltd. 1st Edition |
| 2005 - 2006 | Faculty Teaching Award, The University of Texas MD Anderson Cancer Center |
| 2004 | Head and Neck Surgery Honor Award, American Academy of Otolaryngology |
| 2004 | Julie and Ben Rogers Award for Excellence in Patient Care, The University of Texas MD Anderson Cancer Center |
| 2003 - 2024 | Best Doctors - Leading Expert, Teledoc Health |
| 2003 - 2014 | Best Doctors in America |
| 2002 | Bristol-Myers Squibb Award in Clinical/Translational Research |
| 2000 | Teaching Award, The University of Texas Health Science Center |
| 1999 | Physician/Scientist Program, The University of Texas MD Anderson Cancer Center |
| 1999 | Young Investigator Research Development Award, AAO-HNSF |
| 1995 | George C. Schein Resident Research Competition, The University of Pittsburgh, Department of Otolaryngology |
| 1994 | Francis Davidson Award, Pennsylvania Academy of Otolaryngology |
| 1994 | Research Training Award, Triological Society |
| 1990 | Fellowship, Leukemia Society of America |
| 1990 | Mary Ellis Bell Prize, The University of Pennsylvania School of Medicine |
| 1984 | Medical Scientist Training Program, The University of Pennsylvania |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. U54 award Summary update - The Houston Center for Acquired Resistance Research Updat. Conference. ARTNet- PSRC Joint Annual Meeting. Houston, TX, US.
- 2022. Multidisciplinary Treatment and Team Collaboration. Conference. American Dental Association. Houston, TX, US.
- 2021. Gain of Function on Mutant TP53s Impact on the Head and Neck Squamous Cell Carcinoma Tumor Micro-Environment. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2017. Neoadjuvant and Surgical Approaches for HNSCC. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Proteomic Profiling and Genomic Drivers of Oral Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Technical and Anatomic Considerations for Sentinel Lymph Node Biopsy for Head and Neck Cancers. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Head and Neck Squamous Cell Cancer: A p53 Disease. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Comprehensive Genomic Characterization of Head and Neck Squamous Cell Carcinoma. Conference. The University of Texas School of Dentistry. Houston, TX, US.
- 2013. Introduction to Characterization of the Cancer Genome. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Genomic Alterations in Head and Neck Cancer and What To Do About Them. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Cancers. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Surgical Treatment of Cancer of the Oral Cavity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Oral Oncology: Oncologic Dentistry & Maxillofacial Prosthetics Symposium. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Surgical Management of Oral Cavity Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2021. The Biology and Clinical Behavior of Oral Tongue Cancer. Conference. UT Health San Antonio School of Dentistry, US.
- 2021. Post-op trial for high risk patients, incorporating p53 testing. Conference. ECOG-ACRIN Cancer Research Group - Spring 2021 Virtual Group Meeting, US.
- 2021. Gain of Function Mutant TP53's Impact on the Head and Neck Squamous Cell Carcinoma Tumor Micro-Environment. Conference. Case Western Reserve University School of medicine, US.
- 2018. Immunoprevention of Oral Cancer. Conference. NIH. Rockville, MD, US.
- 2015. Head and Neck Cancer Genomics: Where do we go from here?. Conference. Texas Association of Otolaryngology. Austin, TX, US.
- 2015. Head and Neck Cancer Genomics: Where do we go from here?. Conference. The University of Texas Medical Branch. Galveston, TX, US.
- 2014. Head and Neck Cancer Genomics: Where do we go from here?. Conference. The University of Texas Medical Branch. Galveston, TX, US.
- 2002. Overview of Head and Neck Melanoma. Conference. Texas Society of Ophthalmology and Otolaryngology. Galveston, TX, US.
- 2000. What Primary Care Physicians Need to Know About Head and Neck Cancer. Conference. Texas Medical Association. San Antonio, TX, US.
National Presentations
- 2025. Fireside Chat with Dr. Jeffrey Myers. Invited. New York Head and Neck Society President's Night. New York, New York, US.
- 2024. Pathways to Leadership in Otolaryngology. Panelist. Three Rivers Otolaryngology Update. Pittsburgh, PA, US.
- 2024. Keynote Lecture: Moving The Needle in ATC: A multi-disciplinary bench to beside Journey. Invited. Three Rivers Otolaryngology Update. Pittsburgh, PA, US.
- 2024. Early Career Investigators. Invited. ARTNet-PSRC Joint Annual Meeting. Houston, TX, US.
- 2024. The Houston Center for Acquired Resistance Research Update. Invited. ARTNet-PSRC Joint Annual Meeting. Houston, TX, US.
- 2023. Head and Neck Surgical Oncology Fellow Training Around the World. Panelist. 2023 AAO-HNSF Annual Meeting. Nashville, TN, US.
- 2021. Management of ORL Cancer in 2021. Invited. National Bulgarian ORL Congress, US.
- 2021. Mutant p53 gains oncogenic functions through a cytosolic DNA response. Invited. Biology of Cancer: Microenvironment & Metastasis virtual conference, US.
- 2019. The Biology and Clinical Behavior of Oral Tongue Cancer. Invited. 6th Updates in the Management of Head and Neck Cancer Sympoisum. Atlanta, GA, US.
- 2019. Head and Neck Cancer: Multidisciplinary Approach, Treatment, and Survivorship. Invited. Living Beyond Cancer A-Z. San Antonio, TX, US.
- 2018. Targeting Co-dependent Molecular Pathways in Oral Cancer. Invited. National Institute of Dental & Craniofacial Research (NIDCR): Special Session. Bethesda, MD, US.
- 2018. The Future: Targeted Molecular Therapies. Invited. 2018 Multi-Disciplinary Head and Neck Cancer Care Conference (The Era of Innovation). La Jolla, CA, US.
- 2018. Multi-Disciplinary Treatment for Oral Cancer. Invited. 2018 Multi-Disciplinary Head and Neck Cancer Care Conference (The Era of Innovation). La Jolla, CA, US.
- 2018. Cadaver Lab, Robotic & Laser Endoscopy. Invited. 2018 Multi-Disciplinary Head and Neck Cancer Care Conference (The Era of Innovation). La Jolla, CA, US.
- 2017. Personalizing HNSCC treatment based on TP53 mutational status. Conference. AACR-AHNS Head and Neck Cancer Conference. San Diego, CA, US.
- 2017. Molecular Biology of Head and Neck Cancer Detection. Conference. NCI. San Diego, CA, US.
- 2016. Current Management of Oral Cavity Cancer. Conference. American Head and Neck Society. Seattle, WA, US.
- 2015. 2nd Annual Head & Neck Tumor Imaging and Management: A Multi-disciplinary Approach Symposium. Invited. Educational Symposia. Las Vegas, NV, US.
- 2015. Head and Neck Cancer Genomics: Where do we go from here?. Invited. 2014 Annual AHNS Meeting. Boston, MA, US.
- 2014. Head and Neck Oncology in Wine Country: Multi-disciplinary Approach and Tumor Boards. Invited. Educational Symposia. Napa, CA, US.
- 2014. HN SPORE Workshop. Conference. National Cancer Institute. Rockville, US.
- 2013. The Role of the Head and Neck Team in the Era of Personalized Cancer Care. Invited. 60th Annual AAMP Meeting and 10th Biennial ISMR Meeting. Santa Ana Pueblo, NM, US.
- 2013. Keynote Presentation: Genomics, Cancer and Personalized Medicine. Invited. 25th Annual Symposium. Houston, TX, US.
- 2013. Head & Neck Oncology on the High Seas. Invited. Educational Symposia.
- 2013. Translating the Technical Aspects of Genomic Evaluations into a Clinical Lexicon. Invited. 2013 ASCO Annual Meeting. Chicago, IL, US.
- 2013. Personalizing Head and Neck Cancer Treatment. Invited. The Winship Grand Rounds Lecture Series. Atlanta, GA, US.
- 2013. Molecular Markers in Malignant Melanoma. Invited. The American Laryngological, Rhinological and Otological Society. Orlando, FL, US.
- 2013. Head and Neck Genomics as a Gateway to Personalizing Treatment Decisions. Invited. 9th Salivary Glands and Exocrine Biology Gordon Research Conference. Galveston, TX, US.
- 2012. The Role of Team the Head and Neck Team in the Era of Personalized Cancer Care. Invited. AAMP-ISMR International Congress on Maxillofacial Rehabilitation. Baltimore, MD, US.
- 2012. Scientific Advisory Committee Meeting. Conference. University of Pittsburgh - Department of Otolaryngology. Pittsburgh, PA, US.
- 2012. SPORE Review Meeting. Conference. National Cancer Institute. Rockville, MD, US.
- 2012. Genomic Characterization of Oral Squamous Cell Carcinoma and Management of the N(+) Neck in Oral Cancer. Invited. 53rd Congress of the Korean Association of Oral and Maxillofacial Surgeons. Seoul.
- 2012. New and Old Targets as Prognostic and Therapeutic Biomarkers in Head and Neck Cancer. Invited. AACR Annual Meeting 2012. Chicago, IL, US.
- 2011. Making Cancer History Seminar. Invited. The University of Texas MD Anderson Cancer Center. Aspen, CO, US.
- 2011. Grand Rounds Lecture. Invited. MEEI. Boston, MA, US.
- 2011. Tumor Progression and Metastasis. Conference. NIH. Alexandria, VA, US.
- 2011. Working Towards Personalized Head and Neck Cancer Therapy in Head and Neck Squamous Cell Carcinoma. Conference. 2011 AACR Annual Meeting. Orlando, FL, US.
- 2010. Oral Cancer Genome Sequencing Project Meeting. Conference. NIH-NIDCR. Bethesda, MD, US.
- 2010. Surgical Treatment of Cancer of the Oral Cavity/Oropharynx. Conference. Current Concepts in Head and Neck Surgery. Houston, TX, US.
- 2010. Endoscopic Treatment of Early Glottic Cancer: Past, Present and Future. Invited. Turkish National Otorhinolaryngology and Head and Neck Surgery Congress. Seoul.
- 2010. Disruptive p53 mutations are associated with poor outcome among patients with advanced head and neck squamous cell carcinoma treated with surgery and post-operative radiation. Conference. 15th International p53 Workshop. Philadelphia, PA, US.
- 2010. Disruptive p53 mutations are associated with poor outcome among patients with advanced head and neck squamous cell carcinoma treated with surgery and post-operative radiation. Invited. 15th International p53 Workshop. Philadelphia, PA, US.
- 2010. AAO-HNSF Meeting & OTO EXPO. Conference. AAO-HNSF. Boston, MA, US.
- 2010. Squamous Cell Carcinoma in Fanconi Anemia Patients. Invited. Fanconi Anemia Research Fund. Chicago, IL, US.
- 2009. Targeting Angiogenesis and EGFR. Conference. NCI Translational Science Meeting. Vienna, VA, US.
- 2009. Do We Need a Central Repository for Head and Neck Cell Lines?. Invited. 2009 NCI Translational Science Meeting. Vienna, VA, US.
- 2008. Personalizing the Role of Taxanes and Platinum Compounds for the Treatment of Head and Neck Cancer. Invited. First Annual Symposium on Personalized Therapies of Lung Cancer and Head and Neck Cancer. Chicago, IL, US.
- 2008. Organ Preservation and Conservation Surgery of the Hypopharynx and Larynx. Conference. Ryals Program - Head and neck Cancer: Radiology and Surgery for the Practicing Physician. Scottsdale, AZ, US.
- 2008. Cancer of the Oral Cavity and Oropharynx. Conference. Ryals Program - Head and neck Cancer: Radiology and Surgery for the Practicing Physician. Scottsdale, AZ, US.
- 2008. Melanoma of the Head and Neck. Conference. Ryals Program - Head and Neck Cancer: Radiology and Surgery for the Practicing Physician. Scottsdale, AZ, US.
- 2007. Oral Cancer Progression and Metastasis. Invited. Oral Health Science Seminar Series. Ann Arbor, MI, US.
- 2007. Treatment Choices for Cancer of the Oropharynx. Conference. 2007 Current Concepts in Head and Neck Surgery. New York, NY, US.
- 2007. Melanoma of the Head and Neck. Conference. 2007 Current Concepts in Head and Neck Cancer. New York, NY, US.
- 2007. Targeted Therapy in Head and Neck Cancer: Reality and Future Perspectives. Conference. 7th Head and Neck Workshop: Oral and Oropharyngeal Cancer Update. Seoul.
- 2007. Management of the Neck in Oral and Oropharyngeal Cancers. Conference. 7th Head and Neck Workshop: Oral and Oropharyngeal Cancer Update. Seoul.
- 2007. New Therapeutic Approaches for Thyroid Cancer: Experimental Studies. Conference. Seoul National University. Seoul.
- 2007. Tongue Cancer: Improving Outcomes Through Treatment Intensification and Translational Research. Conference. Samsung Medical Center. Sungkyunkwan University, LA, US.
- 2007. Molecular Targeted Treatment. Conference. 7th Head and Neck Workshop: Oral and Oropharyngeal Cancer Update: From Bench to Bed. Seoul.
- 2007. Tongue Cancer: Improving Outcomes Through Treatment Intensification and Translational Research. Conference. University of Washington. Seattle, WA, US.
- 2007. Tongue Cancer: Improving Outcomes through Treatment Intensificatin and Translational Research. Invited. 7th Annual Otolaryngology Faculty Research Day. Galveston, TX, US.
- 2007. VEGF: A Molecular Target for Cancer Therapy. Conference. Pathology of the 21st Century. Houston, TX, US.
- 2007. Coordination of Comprehensive Head and Neck Care Planning. Invited. Head and Neck Retreat. Baton Rouge, LA, US.
- 2007. What do you mean by Cancer of the "Oral" Tongue?. Invited. Fidler Family Reunion Seminar. Houston, TX, US.
- 2006. Tongue Cancer: Intensification of Therapy and Pathways of Progression. Conference. Arkansas Cancer Research Center. Little Rock, AR, US.
- 2006. Tongue Cancer 2006. Invited. LSU ENT Didactic Day. Baton Rouge, LA, US.
- 2006. Management of Melanoma in the Head and Neck Region. Invited. LSU ENT Didactic Day. Baton Rouge, LA, US.
- 2006. Mentoring the Surgeon-Scientist. Invited. Society of University Otolaryngologists. Washington, DC, US.
- 2006. Adenoid Cystic Carcinoma: Challenges Encountered in Studying Orphan Illness. Invited. Siciliano Lecture. Pittsburgh, PA, US.
- 2006. Adjuvant Treatment for Advanced Cutaneous Head and Neck Melanoma. Invited. American College of Surgeons 92nd Annual Clinical Congress. Chicago, IL, US.
- 2006. Integrating Targeted Therapy: Multidisciplinary Perspectives Symposium. Invited. 2006 AHNS Annual Meeting. Chicago, IL, US.
- 2006. Targeted Therapy in the Management of Aggressive Thyroid Cancers. Invited. 2006 AHNS Annual Meeting & Research Workshop. Chicago, IL, US.
- 2006. ACOSOG: Opportunities and Obstacles in Surgical Research. Invited. 2006 AHNS Annual Meeting & Research Workshop. Chicago, IL, US.
- 2006. Cutaneous Melanoma of the Head & Neck Region. Invited. Texas Association of Otolaryngology H&N Surgery Annual Meeting. Houston, TX, US.
- 2006. Extracapsular Spread: A Common Adversary Across the Generations. Invited. Festschrift in Honor of Dr. Eugene Myers. Pittsburgh, PA, US.
- 2006. Overview on Management of Laryngeal Cancer. Invited. 2006 Comprehensive Course on Multidisciplinary Management of H&N Cancer and Thyroid and Parathyroid Diseases. New York, NY, US.
- 2006. Targeted Molecular Therapy of Head and Neck Cancer. Invited. Oncologic Dentistry & Maxillofacial Prosthetics Symposium. Houston, TX, US.
- 2006. Anti-angiogenic Strategies in Thyroid Cancer. Invited. Fourth Annual Opinion Leader Consortium on Novel & Targeted Therapies for Head and Neck Cancer. Key Biscayne, FL, US.
- 2006. Targeting Tongue Cancer in 2006. Invited. Cancer Metastasis Research Program Seminar Series. Houston, TX, US.
- 2005. Preservation of the Larynx: Current Standards of Care. Invited. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting. Los Angeles, CA, US.
- 2004. Contemporary Management of Malignant Melanoma. Invited. Annual Fall Scientific Assembly. Atlanta, GA, US.
- 2004. Tongue Cancer 2004. Invited. The Third International Chicago Symposium on Malignancies of the Chest and Head & Neck. Chicago, IL, US.
- 2004. New Treatment Paradigms in Head and Neck Melanoma. Invited. American College of Surgeons 90th Annual Clinical Congress. New Orleans, LA, US.
- 2004. Preservation of the Larynx: What are the Current Standards of Care?. Conference. American Society of Clinical Oncology (ASCO). New Orleans, LA, US.
- 2004. Targeting Angiogenesis and Metastasis. Invited. Head and Neck Cancer: Research and Therapeutic Opportunities Meeting. Washington, DC, US.
- 2003. Neck Dissection After Radio- and/or Chemotherapy for Laryngeal and Pharyngeal Tumors. Conference. 2nd International Conference on Cancer of the H&N. Pittsburgh, PA, US.
- 2003. Neck Dissection After Radio- and/or Chemotherapy for Laryngeal and Pharyngeal Tumors. Invited. 2nd International Seminar on Cancer of the Head and Neck. Pittsburgh, PA, US.
- 2003. Targeting EGFR for Chemoprevention of Head and Neck Cancer. Invited. 11th SPORE Investigators’ Workshop. Baltimore, MD, US.
- 2003. PET in Head and Neck Oncology: What can it do for you lately?. Invited. Houston Otologic Society. Houston, TX, US.
- 2003. Oropharyngeal Cancer: Management of the Neck, EGF-R Targeted Molecular Therapy of Head and Neck Cancer, Papillary Thyroid Cancer: Management of the Neck. Invited. University of Pittsburgh. Pittsburgh, PA, US.
- 2002. PI3-K/AKT Signaling in Oral Cancer Progression. Invited. Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Washington, DC, US.
- 2002. Adjuvant Radiotherapy in the Management of Desmoplastic Melanoma. Invited. AAO-HNS. San Diego, CA, US.
- 2002. Elective Neck Dissection During Salvage Laryngectomy. Invited. AAO-HNS. San Diego, CA, US.
- 2002. Small Molecules Directed Against the EGFR Pathway for NSCLC and Head and Neck Cancer. Invited. Unknown. San Francisco, CA, US.
- 2002. Small Molecules Directed Against the EGFR Pathway for NSCLC and Head and Neck Cancer. Invited. 8th Annual ASCO Meeting. New York City, NY, US.
- 2002. Overview of Head and Neck Melanoma. Invited. Texas Society of Ophthalmology and Otolaryngology. Galveston, TX, US.
- 2002. Tongue Cancer 2002. Invited. High Altitude/Masters in Otolaryngology Meeting. Park City, UT, US.
- 2002. Mechanisms of Metastasis of Oral Tongue Cancer. Invited. The Helmuth Goepfert Society. Houston, TX, US.
- 2002. Perineural Invasion Predicts Local Recurrence and Disease-Specific Survival in Mucosal Head and Neck Squamous Cell Carcinoma. Conference. Southern Section, Triological Society. Captiva Island, FL, US.
- 2001. Tongue Base Cancer and Melanoma – Current Concepts. Conference. Otolaryngology Update: 2001. San Francisco, CA, US.
- 2001. Sentinel Lymph Node Mapping in Melanoma: A Powerful Prognostic Procedure. Invited. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. San Francisco, CA, US.
- 2001. Oral Tongue Cancer: Evaluation and Management. Invited. American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting. Washington, DC, US.
- 2001. Comprehensive Management of Cutaneous Melanoma of the Head and Neck and Oral Tongue Cancer: Evaluation and Management. Invited. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting. Denver, CO, US.
- 2001. Biochemoprevention for Laryngeal Premalignancy and Laryngopharyngeal Reflux Disease: A Potential Risk Factor for Laryngeal Premalignancy. Invited. Multidisciplinary Management of Laryngeal Carcinoma Conference. Tacoma, WA, US.
- 2001. A Statistical Model To Predict Distant Metastases From Head and Neck Squamous Cell Carcinoma. Conference. The American Head and Neck Society Annual Meeting. Palm Desert, CA, US.
- 2001. A Prospective Study of Intraoperative Lymphatic Mapping for Head and Neck Cutaneous Melanoma. Conference. The American Head and Neck Society Annual Meeting. Palm Desert, CA, US.
- 2001. Applications of Lymphoscintigraphy and Sentinel Node Biopsy, and Cutaneous Melanoma – Case Management. Invited. American Academy of Otolaryngology-Head and Neck Surgery Foundation 14th Annual Cherry Blossom Conference. Washington, DC, US.
- 2000. Comprehensive Management of Head and Neck Melanoma. Invited. American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting. Washington, DC, US.
- 2000. Therapy of Squamous Cell Carcinoma of the Oral Cavity (SCCOC) With PK1166, A Novel Epidermal Growth Factor Receptor (EGF-R) Inhibitor. Conference. 5th International Conference on Head and Neck Cancer. San Francisco, CA, US.
- 2000. Cutaneous Melanoma (CM) Arising From Non-Head and Neck Primary Sites with Sentinel Lymph Nodes (SLN) in the Neck. Conference. 5th International Conference on Head and Neck Cancer. San Francisco, CA, US.
- 2000. Clinicopathologic Predictors of Distant Metastases From Head and Neck Squamous Cell Carcinoma. Conference. 5th International Conference on Head and Neck Cancer. San Francisco, CA, US.
- 2000. Influence of Biopsy Type on the Prognosis of Cutaneous Malignant Melanoma (CM) of Head and Neck: A Follow-up Study. Conference. 5th International Conference on Head and Neck Cancer. San Francisco, CA, US.
- 2000. Biochemopreventive Therapy and Laryngeal Premalignancy. Invited. High Altitudes/Masters in Otolaryngology. Vail, CO, US.
- 1999. Management of Malignant Melanoma of the Head and Neck Region. Invited. American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting. New Orleans, LA, US.
International Presentations
- 2025. Oral Cancer: Lots Of Scientific Progress With Limited Improvement In Clinical Outcomes. Invited. 83rd Annual Herbert S. Birkett Memorial Lecture. Montreal, CA.
- 2025. Burden of HPV-related diseases and cancers in males. Invited. Asian Society of Head and Neck Oncology Scientific Conference. Ho Chi Minh City, VN.
- 2025. Special Breakfast w/ Prof. Jeffrey N. Myers. Invited. Asian Society of Head and Neck Oncology (ASHNO) Scientific Conference. Ho Chi Minh City, VN.
- 2025. “Keynote: Oral Cancer Treatment in 2025. Invited. Asian Society of Head and Neck Oncology Scientific Conference. Ho Chi Minh City, VN.
- 2025. The Role of the Otolaryngologist-Head and Neck Surgeon in Caring for the Oropharyngeal Cancer Patient. Invited. Multidisciplinary Approaches in Head and Neck Oncology and Laryngology: Progress and Innovations. Kaunas, LT.
- 2025. The Role of Neoadjuvant Systemic Therapy in the Treatment of Head and Neck Cancer. Invited. Multidisciplinary Approaches in Head and Neck Oncology and Laryngology: Progress and Innovations. Kaunas, LT.
- 2025. Keynote Lecture: The Biology and Clinical Behavior of Oral Tongue Cancer. Invited. Multidisciplinary Approaches in Head and Neck Oncology and Laryngology: Progress and Innovations. Kaunas, LT.
- 2024. International leaders in Head & Neck Surgery: Shaping the Future of Global Care. Invited. 117th Annual Congress of the Taiwan Society of Otorhinolaryngology Head and Neck Surgery. Kaohsiung City, TW.
- 2024. Leading the way in Tongue Cancer Treatment: Multidisciplinary Strategies from MD Anderson. Invited. 117th Annual Congress of the Taiwan Society of Otorhinolaryngology Head and Neck Surgery. Taipei, TW.
- 2024. Keynote Lecture: HPV Negative Head and Neck Squamous Cell Carcinoma: Lots of Scientific Progress-Limited Improvements in Clinical Outcomes. Invited. 117th Annual Congress of the Taiwan Society of Otorhinolaryngology Head and Neck Surgery. Kaohsiung City, TW.
- 2023. Treatment of Pharyngoesophageal Cancer. Invited. 7th World Congress of the International Federation of Head and Neck Oncologic Societies. Rome, IT.
- 2021. Panelist: Systemic Therapy. Invited. International Federation of Head and Neck Oncologic Societies World Head and Neck Virtual Tour, US.
- 2019. The Role of the Otolaryngologist - Head & Neck Surgeon in Caring for the Oropharyngeal Cancer Patient. Invited. 2019 Regional Institute of Oncology IASI Conference. Isla, RO.
- 2019. Update on Oropharyngeal Cancer Treatment - Management of Melanoma of the Head & Neck Region. Invited. 2019 Regional Institute of Oncology IASI Conference. Isla, BG.
- 2019. Management of Melanoma of the Head & Neck Region. Invited. Bulgarian ENT Congress. Plovdiv, BG.
- 2019. Update on Oropharyngeal Cancer Treatment. Invited. Bulgarian ENT Congress. Plodiv, BG.
- 2019. Oral Cancer & The Microbiome. Invited. 2019 IAOO Conference. Rome, IT.
- 2019. Debate 57: Radiotherapy or Reexcision After R1 Resections in Oral & Oropharyngeal Cancer. Invited. 2019 IAOO Conference. Rome, IT.
- 2019. Prediction & Mgmnt of Wound Infections & Complications. Invited. 2019 IAOO Conference. Rome, IT.
- 2018. Panelist: Stump the Faculty Panel and Audience Discussion. Invited. Current Concepts in Head and Neck Surgery. Toronto, CA.
- 2018. Melanoma: Surgical Management of Local and Recurrent Disease. Invited. Current Concepts in Head and Neck Surgery. Toronto, CA.
- 2018. Debate with Q&A: Sentinel Node Biopsy in Oral Cavity Cancer. Invited. Current Concepts in Head and Neck Surgery. Toronto, CA.
- 2018. Key Note Speaker. Conference. International Oropharyngeal Cancer Symposium 2018. Guangzhou, CN.
- 2017. Melanoma of the Head and Neck Region. Invited. Annual Meeting of the Israeli Society of Otolaryngology-Head and Neck Surgery. Eilat, IL.
- 2017. Cancer of the Larynx. Invited. Annual Meeting of the Israeli Society of Otolaryngology-Head and Neck Surgery. Eilat, IL.
- 2017. Head and Neck Cancer Genomics. Invited. Annual Meeting of the Israeli Society of Otolaryngology-Head and Neck Surgery. Eilat, IL.
- 2017. Oral Cavity Cancer (Instructional Course). Invited. Annual Meeting of the Israeli Society of Otolaryngology-Head and Neck Surgery. Eilat, IL.
- 2016. Understanding the Causes and Impact of Extra-Nodal Spread in Oral Cancer. Invited. 101st Academy Meeting of Taiwan Otolaryngological Society. Taoyuan, TW.
- 2016. What is the role of TORS in the Treatment of Oropharyngeal Cancer. Invited. 2nd AIN Shams ORL-HNS Academy. Heliopolis, Cairo, EG.
- 2016. Head and Neck Genomics: Where Do We Go From Here?. Invited. 6th Emirates Otorhinolaryngology Audiology and Communication Disorders Congress in Joint Meeting with The American Academy of Otolaryngology Head and Neck Surgery. Dubai, AE.
- 2015. Head & Neck Oncology Symposia at Sea. Invited. Educational Symposia, DK.
- 2015. Translational Research. Invited. 4th Congress of the Asian Society of Head and Neck Oncology (ASHNO 2015) and 39th Annual Meeting of Japan Society for Head and Neck Cancer. Kobe, JP.
- 2015. Surgical Techniques, Functional Reconstruction, Sentinal Node Mapping, Chair. Invited. 2015 ASCO Annual Meeting. Chicago, US.
- 2014. Personalizing Head and Neck Cancer. Invited. The 50th Annual Meeting of the South African Society of Otorhinolaryngology, Head and Neck Surgery. Cape Town, ZA.
- 2014. Chair, The Molecular Tools in Diagnosis, Prognosis and Treatment. Invited. 5th World Congress of the International Federation of Head and Neck Oncologic Societies (IFHNOS) and the American Head and Neck Society Annual Meeting. New York, US.
- 2014. Emerging Findings in Head and Neck Cancer. Invited. IARC (International Agency for Research on Cancer), IT.
- 2014. Personalizing Head and Neck Cancer. Invited. CHUV - Centre Hospitalier Universitaire Vaudois. Lausanne, CH.
- 2013. Comprehensive Genomic Characterization of Head and Neck Cancers. Invited. Taipei Veterans General Hospital and Chang Gung Memorial Hospital. Taipei, TW.
- 2013. Overcoming Mutant p53 Mediated Resistance in Head and Neck Cancer. Invited. Congress - Next Frontiers to Cure Cancer. Sao Paulo, BR.
- 2013. Genomic Alterations in Head and Neck Cancer: What to Do About Them. Invited. Congress - Next Frontiers to Cure Cancer. Sao Paulo, BR.
- 2013. Personalizing Head and Neck Cancer Treatment. Invited. Shanghai Center of Head and Neck Oncology Conference. Shanghai, CN.
- 2012. Personalizing Head and Neck Cancer Therapy. Invited. 2012 NCRI Cancer Conference. Liverpool, GB.
- 2012. Personalizing Head and Neck Cancer Treatment. Invited. 63 Congreso Nacional de la Sociedad Española De Otorrinolaringología y Patología Cérvico-Facial. Oviedo, ES.
- 2012. Integrated Head and Neck Cancer Genomics. Invited. 8th International Conference on Head and Neck Cancer. Toronto, CA.
- 2012. Comprehensive Genomic Characterization of Oral Squamous Cell Carcinoma. Invited. 31st Annual Convention of the Indian Association for Cancer Research. Mumbai, IN.
- 2012. Genomics of Oral Cancer and New Therapeutic Opportunities. Invited. Sino-US Symposium on Head and Neck Cancer. Guangzhou, CN.
- 2011. Genetic Changes in Oral Cancer. Invited. International Oral Cancer Symposium. Bangkok, TH.
- 2011. Personalized Head and Neck Cancer Therapy, Nodal Metastases of Oral Cavity Cancer, Contemporary Management of Oropharyngeal Cancer, Head and Neck Melanoma. Invited. Israeli Society of Head and Neck Surgery and Oncology. Jerusalem, IL.
- 2011. Personalized Cancer Medicine and Melanoma in the Head and Neck Region. Conference. p53 Collaborative Study. Sao Paulo, BR.
- 2010. Round Table: Oral Tongue Cancer. Invited. LXVII Chilean Congress Otolaryngology, Head and Neck Surgery. Valdivia, CL.
- 2010. Management of Melanoma of the Head and Neck Region. Invited. LXVII Chilean Congress Otolaryngology, Head and Neck Surgery. Valdivia, CL.
- 2010. Personalize Cancer Therapy. Invited. LXVII Chilean Congress Otolaryngology, Head and Neck Surgery. Valdivia, CL.
- 2010. Adenoid Cystic Carcinoma. Invited. LXVII Chilean Congress Otolaryngology, Head and Neck Surgery. Valdivia, CL.
- 2010. Oropharyngeal Cancer. Invited. Turkish National Otorhinolaryngology and Head and Neck Surgery Congress. Antalya, TR.
- 2010. Personalized Cancer Therapy. Invited. Turkish National Otorhinolaryngology and Head and Neck Surgery Congress. Antalya, TR.
- 2010. Personalizing Approaches to the Treatment of Head and Neck Cancer. Invited. International Federation of Head and Neck Oncologic Societies (IFHNOS). Seoul.
- 2008. Larynx and Hypopharynx Case Presentation. Conference. Ryals Program - Head and Neck Cancer: Radiology and Surgery for the Practicing Physician. Scottsdale, US.
- 2008. General Principles for Treatment Selection. Invited. Statements 2008 on Head and Neck Cancer. Frankfurt, DE.
- 2007. The Effect of Vandetanib, a VEGFR-2 and EGFR Tyrosine Kinase Inhibitor, in an Orthotopic Nude Mouse Model of Human Adenoid Cystic Carcinoma. Conference. 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, US.
- 2007. Targeted Therapy in Head and Neck Cancer: Reality and Future Perspectives. Invited. XII Curso Internacional de Atualizacao em Cirurgia de Cabeca e Pescoco 2007. Sao Paulo, BR.
- 2007. Organ-Preservation Protocols: Future Prospectives. Invited. XII Curso Internacional de Atualizacao em Cirurgia de Cabeca e Pescoco 2007. Sao Paulo, BR.
- 2007. Tecnicas de reconstrucao apos laringectomia parcial vertical. Invited. XII Curso Internacional de Atualizacao em Cirurgia de Cabeca e Pescoco 2007. Sao Paulo, BR.
- 2007. Surgical Organ Preservation of Laryngeal Cancer: Future Perspectives. Invited. XII Curso Internacional de Atualizacao em Cirurgia de Cabeca e Pescoco 2007. Sao Paulo, BR.
- 2007. Pharyngoesophageal Reconstruction: Future Perspectives. Invited. XII Curso Internacional de Atualizacao em Cirurgia de Cabeca e Pescoco 2007. Sao Paulo, BR.
- 2007. New Therapeutic Approaches for Thyroid Cancer: Experimental Studies. Invited. Journee de medeine Nucleaire et de Cancerologie Endocrinien. Villejuif, FR.
- 2006. Contemporary Management of Head and Neck Melanoma. Invited. AAO-HNSF. Toronto, CA.
- 2006. Targeted Molecular Therapy of Head and Neck Cancer. Invited. Frontiers in Otorhinolaryngology 2006. Queensland, AU.
- 2006. Tongue Cancer: Improving Outcomes Through Treatment Intensification and Translational Research. Invited. Frontiers in Otorhinolaryngology 2006. Queensland, AU.
- 2006. Biology of HNC: From Bench to Bedside. Invited. 3rd Annual World Congress of International Federation of Head and Neck Oncologic Societies. Prague, CZ.
- 2006. Modern Treatment Options. Invited. Scientific Board – Statements on Head and Neck Cancer. Frankfurt, DE.
- 2005. Surgical Management - N0 & N+ Neck in Oral Cancer. Invited. Multidisciplinary Head and Neck Cancer Symposium. Mumbai, IN.
- 2005. A Day at ACTREC, Advanced Center for Teaching, Research and Education in Cancer. Invited. Head and Neck Symposium at Tata Memorial. Mumbai, IN.
- 2005. Current Concepts in the Treatment of Oral Tongue Squamous Cell Carcinoma. Invited. XX Brazilian Congress on Head and Neck Surgery. Salvador, BR.
- 2005. Targeted Molecular Therapy of Head and Neck Cancer. Invited. XX Brazilian Congress on Head and Neck Surgery. Salvador, BR.
- 2005. Cutaneous melanoma of the Head and Neck Region. Invited. XX Brazilian Congress on Head and Neck Surgery. Salvador, BR.
- 2005. Cutaneous Melanoma of the Head and Neck Region, Current Concepts in the Treatment of Oral Tongue Squamous Cell Carcinoma, Targeted Molecular Therapy of Head and Neck Cancer. Invited. XX Brazilian Congress on Head and Neck Surgery. Salvador, BR.
- 2005. Targeted Therapy of Head and Neck Cancer. Invited. Scientific Programme of the XVIII International Federation of Otolaryngology Societies World Congress. Rome, IT.
- 2005. Targeted Therapy of Head and Neck Cancer. Invited. the XVIII International Federation of Otolaryngology Societies World Congress. Rome, IT.
- 2005. Molecular Factors in H&N CA: What the Radiologist Needs to Know About Angiogenesis, EGF and Just What is p53?. Invited. American Society of Neuroradiology Society Annual Meeting. Toronto, CA.
- 2004. Sentinel Node Biopsy of Management in Melanoma of the H&N, Round Table – Reflux, How Reflux Factors the Risk in Cancer of the Larynx. Invited. XXVI Congreso Nacional Fesormex. Acapulco, MX.
- 2004. The Effects of the Dual EGF-R and VEGF-R, Kinase Inhibitor, AEE788, on Head and Neck Cancer: In Vitro and In Vivo Results. Invited. The Second Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer. Montego Bay, JM.
- 2003. Neck Dissection for Thyroid Carcinoma and Elective and Therapeutic Selective Neck Dissection in Squamous Cell Carcinoma of the Oral Tongue. Invited. International Course: Multidisciplinary Approach on Neck Metastases and Thyroid Gland Meeting. Zagreb, HR.
- 2003. PI-3 Kinase/AKT in Progression of Oral Tongue Cancer: A Potential Therapeutic Target. Invited. The First Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer. San Juan, PR.
- 2002. Laryngopharyngeal Reflux as a Risk Factor for Laryngeal Malignancy. Invited. Hong Kong Surgical Forum. Guangzhou, CN.
- 2002. A Mouse Model of Oral Tongue Cancer Metastasis. Invited. Hong Kong Surgical Forum, Joint Symposium. Guangzhou, CN.
- 2002. Biochemopreventive Therapy of Laryngeal Premalignancy. Invited. Hong Kong Surgical Forum. Guangzhou, CN.
- 2002. Squamous Cell Carcinoma of the Oral Tongue; The Significance of Nodal Disease. Invited. Hong Kong Surgical Forum. Guangzhou, CN.
- 2001. Advances in Experimental and Clinical Research. Invited. International Symposium on Metastases in Head and Neck Cancer. Marburg, DE.
Formal Peers
- 2024. Keynote Lecture: Moving The Needle in ATC: A multi-disciplinary bench to beside Journey. Invited. Pittsburgh, PA, US.
- 2023. TP53 Mutation and the Tumor Microenvironment. Visiting. Cleveland, OH, US.
- 2023. The Role of Neoadjuvant Systemic Therapy in the Treatment of Head and Neck Cancer. Visiting. New Haven, CT, US.
- 2021. The Biology and Clinical Behavior of Oral Tongue Cancer. Invited, US.
- 2020. 2020 Otolaryngology Grand Rounds The Role of the Otolaryngologist-Head and Neck Surgeon in Caring for the Oropharyngeal Cancer Patient. Invited, US.
- 2019. Keynote Address: Personalizing H&N Cancer Treatment based on TP53 Mutational Status. Invited. Boston, MA, US.
- 2019. How to have a sustainable, enjoyable, and meaningful career as a Physician-Scientist. Visiting. Philadelphia, PA, US.
- 2018. Oropharyngeal Cancer 201: Where Are We Now? Where Do We Need to Go?. Visiting. Kansas City, KS, US.
- 2018. Head & Neck Cancer 2018: Where are We? Where are we Going?. Invited. New York, NY, US.
- 2018. What's New in the Treatment of Melonoma of the Head & Neck Region. Visiting. Little Rock, AR, US.
- 2018. The Role of the Otolaryngologist - Head and Neck Surgeon in Oropharyngeal Cancer Management. Visiting. Little Rock, AR, US.
- 2017. Biomarkers in Head and Neck Cancer. Invited. Ann Arbor, MI, US.
- 2017. New Advances in Translational Research of Oral Cancer. Invited. Columbus, OH, US.
- 2016. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. Visiting. Charleston, SC, US.
- 2016. Personalization of Head and Neck Cancer Therapy. Visiting. Charleston, SC, US.
- 2016. Rugged Individualism versus The Collective Good. Visiting. Bronx, NY, US.
- 2016. Current Standards and new perspectives on the treatment of Oral Cancer. Visiting. Bronx, NY, US.
- 2016. Current Standards and New Perspectives on Treatment of Oral Cancer. Visiting. Calgary, Alberta, CA.
- 2016. Current Standards and New Perspectives on Treatment of Oral Cancer. Visiting. Los Angeles, CA, US.
- 2015. Current Standards and New Perspectives on Treatment of Oral Cancer. Visiting. London, Ontario, CA.
- 2015. Leveraging Genomics to Improve Outcomes for Patients with Oral Squamous Cell Carcinoma. Invited. Ann Arbor, MI, US.
- 2014. Head and Neck Cancer: A p53 Disease. Invited. Nashville, TN, US.
- 2014. Head and Neck Cancer: A p53 Disease. Invited. St. Louis, MO, US.
- 2013. Personalizing Head and Neck Cancer Treatment. Invited. Chicago, IL, US.
- 2012. Management of the N(+) Neck in Oral Cavity Cancer. Visiting. Chapel Hill, NC, US.
- 2012. Personalizing Head and Neck Cancer Therapy. Visiting. Philadelphia, PA, US.
- 2012. Genomics of Oral Cancer and New Therapeutic Opportunities. Invited. New York, NY, US.
- 2011. Grand Rounds - Case Presentations 2011. Visiting. Boston, MA, US.
- 2011. Meetings. Visiting. Boston, MA, US.
- 2011. Epithelial Biology Presentation: Towards a Personalized Approach to Head and Neck Cancer Therapy. Invited. Chicago, IL, US.
- 2010. Targeting Glycolysis in Head and Neck Squamous Cell (HNSCC) in Oder to Improve Therapeutic Outcomes. Visiting. Seoul.
- 2010. Targeted Therapy in H&N Cancer: Where are We?. Visiting. Seoul.
- 2010. Personalizing Approaches to the Treatment of Head and Neck Cancer. Visiting. Seoul.
- 2010. Contemporary Management of Melanoma of the Head and Neck Region. Visiting. St. Louis, MO, US.
- 2010. Resident Research Day. Visiting. St. Louis, MO, US.
- 2010. Personalizing Cancer Therapy in Head and Neck Squamous Cell Carcinoma. Visiting. New York, NY, US.
- 2010. Translational Research. Visiting. New York, NY, US.
- 2008. M. D. Anderson SPORE in Head and Neck Cancer: Overcoming Resistance to EGFR. Visiting. Houston, TX, US.
- 2008. Targeted Therapy in Head and Neck Cancer: Reality and Future Perspectives. Visiting. Taipei, TW.
- 2008. Tongue Cancer: Improving Outcomes through Treatment Intensification and Translational Research. Visiting. Taipei, TW.
- 2008. Contemporary Management of Oropharyngeal Cancer. Visiting. Taipei, TW.
- 2008. Translational Research in Squamous Cell Carcinoma of the Oral Tongue. Visiting. Charleston, SC, US.
- 2008. Tongue Cancer: Improving Outcomes Through Treatment Intensification and Translational Research. Visiting. Los Angeles, CA, US.
- 2008. Statements 2008 on Head and Neck Cancer. Visiting. Frankfurt, DE.
- 2007. Tongue Cancer: Improving Outcomes Through Treatment Intensification and Translational Research. Visiting. Galveston, TX, US.
- 2007. Tongue Cancer: Pathways of Progression of Intensification of Therapy. Visiting. Birmingham, AL, US.
- 2006. Preclinical Assessment of Molecularly-Targeted Agents in Thyroid Cancer. Visiting. Villejuif, FR.
- 2005. Tongue Cancer 2005. Invited. Pittsburgh, PA, US.
- 2005. Tongue Cancer 2005, Grand Rounds. Visiting. Stony Brook, NY, US.
- 2004. Tongue Cancer 2004. Invited. Houston, TX, US.
- 2004. Tongue Cancer 2004, Grand Rounds. Visiting. Pittsburgh, PA, US.
- 2003. Otolaryngology- Head and Neck Surgery. Visiting. Budapest, HU.
- 2002. Hong Kong Surgical Forum. Visiting. Hong Kong, CN.
- 2002. Melanoma-an Update on Surgical Treatment. Invited. Houston, TX, US.
- 2002. Melanoma – an Update on Surgical Treatment. Invited. Houston, TX, US.
- 2000. Melanoma of the Head and Neck. Invited. Houston, TX, US.
- 1999. Biochemopreventive Therapy in Advanced Laryngeal Dysplasia. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment Resistance |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00008074_Rev3/CA242006 |
| Date: | 2023 - 2028 |
| Title: | Metabolic Adaptation Enables Cisplatin Resistance and Inhibits Tumor Immunity |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | FP00016617 |
| Date: | 2023 - 2026 |
| Title: | NIR-Light-Activated Molecular Jackhammers that Eradicate Cancer Cells and Tumors by Vibronic-Driven Action |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP / FP00016981 |
| Date: | 2022 - 2027 |
| Title: | The Houston Center for Acquired Resistance Research (H-CARR) “Administrative Core” |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | FP00014869 |
| Date: | 2022 - 2027 |
| Title: | The Houston Center for Acquired Resistance Research (H-CARR) Project 3: “Quantification of cisplatin sensitivity and resistance using metabolic imaging and circulating tumor cell (CTC) biomarkers” |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | FP00014869 |
| Date: | 2022 - 2027 |
| Title: | The Houston Center for Acquired Resistance Research (H-CARR) Project 2: “Defining the role of KEAP/NRF2 signaling dysregulation and sensory nerve reprograming during acquisition of cisplatin resistance and metastasis in HNSCC” |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | FP00014869 |
| Date: | 2022 - 2027 |
| Title: | The Houston Center for Acquired Resistance Research (H-CARR) Core C “Tumor Model and Biospecimen Repository Core” |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | FP00014869 |
| Date: | 2022 - 2027 |
| Title: | KMT2D as modulator of epigenome and immune microenvironment in HNSCC |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA270361-01A1 |
| Date: | 2022 - 2027 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | U54CA274366 |
| Date: | 2022 - 2027 |
| Title: | Houston Oral Premalignancy center of Excellence (HOPE) Project 3: Genomic alterations disrupt immune surveillance mechanisms in oral premalignant lesions |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | RFA-CA-21-054 |
| Date: | 2022 - 2027 |
| Title: | Functional Roles of GOF TP53 Mutations in Metastasis and Immunosuppression of Head and Neck Cancers |
| Funding Source: | NIH/NIDCR |
| Role: | Co-PI |
| ID: | R01DE030875 |
| Date: | 2021 - 2026 |
| Title: | Developing a Clinical Trial Platform for Local Delivery of Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | ad interim PI |
| ID: | RP210176 |
| Date: | 2021 - 2026 |
| Title: | Targeting Replication Stress and Homologous Recombination Repair Mechanisms in HPV-Positive and Negative Head and Neck Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Collaborator |
| ID: | R01DE030104 |
| Date: | 2021 - 2026 |
| Title: | Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | R01DE030656 |
| Date: | 2021 - 2026 |
| Title: | Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA253090-01 |
| Date: | 2021 - 2026 |
| Title: | Role of KEAP1/NRF2 signaling and epigenetic reprogramming during cisplatin resistance and metastasis in HNSCC |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00011161 |
| Date: | 2020 - 2023 |
| Title: | Defining the Role of Tumor-Neural Crosstalk in Cancer Progression and Treatment Resistance |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Date: | 2020 - 2024 |
| Title: | Defining the Role of Tumor-Neural Crosstalk in Cancer Progression |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| Date: | 2020 - 2025 |
| Title: | Defining the Role of Tumor-Neural Crosstalk in Head and Neck Cancer Progression and Treatment Resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R37CA242006 |
| Date: | 2020 - 2025 |
| Title: | Predicting and Overcoming Chemoradioresistance in p53-Mutant Head and Neck Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| ID: | 2 R01 DE024601-06 |
| Date: | 2020 - 2022 |
| Title: | The Interplay of Inflammation, Genomic Instability, and Immune Microenvironment in Oral Cancer Development |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1R03DE029521-01 |
| Date: | 2020 - 2025 |
| Title: | Mechanisms and Therapeutics in KMT2D-mutant Head and Neck Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1R01DE029571-01 |
| Date: | 2020 - 2022 |
| Title: | Dependence of TP53 Mutant Head and Neck Cancers on PRMT1 |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1R21DE029581-01 |
| Date: | 2020 - 2023 |
| Title: | Tumor-Neural Crosstalk in Head and Neck Cancer Progression and Treatment Resistance |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP200112 |
| Date: | 2019 - 2021 |
| Title: | Overcoming Cisplatin Resistance by Targeting Fatty Acid Metabolism |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | 1R03DE028858-01 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support (Core) Grant - Head and Neck Program (PP9) |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| ID: | 5 P30 CA016672 43 |
| Date: | 2018 - 2023 |
| Title: | Novel Therapeutic Strategies to Target Replication Stress for the Treatment of High-risk HPV-driven HNSCC |
| Funding Source: | NIH/NIDCR |
| Role: | Other Significant Contributor |
| ID: | 1R01DE026470-01A1 |
| Date: | 2017 - 2021 |
| Title: | Sensitizing TP53-mutant Driven Head and Neck Cancer to Therapy |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | FP00000436 |
| Date: | 2017 - 2022 |
| Title: | Genetic Mechanisms Driving Oral Cancer Pain |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Genetic and Epigenetic Mechanisms Driving Oral Cancer Pain |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Genomic Marker of Metastasis |
| Funding Source: | NIH sub through New York University |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Metformin-based Radiosensitization of TP53 Mutant Driven Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA197338-01A1 |
| Date: | 2016 - 2021 |
| Title: | Targeting Focal Adhesion Kinase to Improve Head and Neck Cancer Treatment Response |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA207296-01 |
| Date: | 2016 - 2018 |
| Title: | Trip12 as a Novel Radiation Enhancement Target and Mediator of the Effect of HPV/p16 on Radiotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA205508-01 |
| Date: | 2015 - 2017 |
| Title: | Spore in Head and Neck Cancer - Comprehensive Genomic Characterization of HNSCC Arising in HIV-Infected Individuals |
| Funding Source: | NIH/NIDCR sub through Johns Hopkins University |
| Role: | Site PI |
| ID: | 3 P50 DE019032-14S2 |
| Date: | 2015 - 2021 |
| Title: | Translating Genomic Alterations into Novel Therapeutic Targets in Head and Neck Cancer through Computational and Functional Approaches |
| Funding Source: | NIH/NIDCR |
| Role: | Multi-PI |
| ID: | 5 U01 DE025181-04 |
| Date: | 2015 - 2020 |
| Title: | Mechanisms of Mutant p53’s Gain of Function in Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA190631-01A1 |
| Date: | 2015 - 2018 |
| Title: | Identification of Clinically Relevant Targets for Radiosensitization |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150293 01 |
| Date: | 2015 - 2018 |
| Title: | Identification of clinically relevant targets for radiosensitization |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150293 |
| Date: | 2015 - 2018 |
| Title: | Sensitization of HPV+ HNSCC to Cytotoxic Treatments G2/M Checkpoint with AZ-1775 to Improve Survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP150127 |
| Date: | 2014 - 2018 |
| Title: | Constructing Mechanistic Models of Cancer Signaling by Reading and Inference |
| Funding Source: | DARPA |
| Role: | Co-I |
| Date: | 2014 - 2019 |
| Title: | Force sensing with Nanotubes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2014 - 2017 |
| Title: | Mechanistic roles of gain-of-function mutant p53 in cancer metabolism and cancer inflammation |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP140162 |
| Date: | 2014 - 2021 |
| Title: | Predicting and Overcoming Chemoradioresistance in p53-Mutant Head and Neck Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| ID: | 5R01DE024601-05 |
| Date: | 2014 - 2018 |
| Title: | BCM Big Data to Knowledge Center for Integration, Discovery and Translation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Identification of targetable markers of radiation sensitivity in Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Funding Source: | American Society for Therapeutic Radiology and Oncology (ASTRO) |
| Role: | Mentor |
| Date: | 2014 - 2015 |
| Title: | A Knowledge Integration Tool for Biological Discovery |
| Funding Source: | Baylor College of Medicine |
| Role: | Co-I |
| ID: | N66001-14-1-4027 |
| Date: | 2013 - 2017 |
| Title: | Personalized Cancer Therapy Studies in Head and Neck Squamous Cell Carcinomas (HNSCC) |
| Funding Source: | Kadoorie Charitable Foundation |
| Role: | Co-I |
| ID: | 14027706 |
| Date: | 2013 - 2016 |
| Title: | Multidisciplinary Research Program (MRP) |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | KNIT: A Knowledge Integration Tool for Hypothesis Generator |
| Funding Source: | Baylor College of Medicine |
| Role: | Co-I |
| Date: | 2012 - 2013 |
| Title: | To Study the Ant-Tumor Efficacy of PEITC in an Orthotopic Oral Tongue |
| Funding Source: | Dental Innovation Foundation |
| Role: | PI |
| ID: | DIF 01 |
| Date: | 2012 - 2017 |
| Title: | Institutional National Research Science Award (T32) Training of Academic Head and Neck Surgical Oncologist |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5T32CA060374 15 |
| Date: | 2012 - 2014 |
| Title: | Rapid and Sensitive Diagnostic Testing for Somatic Mutations in Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Site PI |
| ID: | RP121018 02 |
| Date: | 2011 - 2015 |
| Title: | Towards Personalized Cancer Therapy: Stratification of Oral and Pharyngeal Cancer Based on p53 Mutational Status |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP120258 03 |
| Date: | 2011 - 2016 |
| Title: | Acoustic Imaging of Sentinel Node Metastasis Using Plasmonic Nanosensors |
| Funding Source: | NIBIB |
| Role: | Significant Contributor |
| ID: | R01 EB008101 |
| Date: | 2011 - 2013 |
| Title: | Prevalence and Prognostic Significance of Disruptive TP53 Mutations in Oral Cancer around the World |
| Funding Source: | Sister Institution Network Fund (SINF) |
| Role: | Co-PI |
| Date: | 2011 - 2016 |
| Title: | Extension of Radiotherapy Research, Core A |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| ID: | P01CA06294 |
| Date: | 2011 - 2013 |
| Title: | Center for Cellular NanoMechanics |
| Funding Source: | Methodist Hospital Research Institute |
| Role: | Co-I |
| ID: | W81XWH 10 2 0125 02 |
| Date: | 2011 - 2016 |
| Title: | A Transposon-Based Screening for Head and Neck Cancer Genes |
| Funding Source: | NIH/NIDCR |
| Role: | Co-Mentor |
| ID: | K08 DE021177-01 |
| Date: | 2011 - 2013 |
| Title: | Multimodality Therapy of Local-regionally Advanced Head and Neck Squamous Cell Carcinoma using Novel Metal Nanostructures |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP110193 |
| Date: | 2010 - 2015 |
| Title: | Translational Research in Multidisciplinary Programs (TRIUMPH) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Mentor |
| Date: | 2010 - 2015 |
| Title: | Translational Research in Multidisciplinary Program |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | T32CA142514 |
| Date: | 2010 - 2014 |
| Title: | Comprehensive Analysis of Genetic and Epigenetic Changes in Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP100233 02 |
| Date: | 2010 - 2013 |
| Title: | Computational Cancer Biomedicine Training Grant |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RFA R-10-RTA1 |
| Date: | 2010 - 2013 |
| Title: | The Future of Cancer Research: Training Program for Basic and Translational Scientists |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-mentor |
| ID: | RP101502 01 |
| Date: | 2010 - 2015 |
| Title: | Tumor Repository, Histology, and Laboratory Support Facilities - Core A |
| Funding Source: | NIH/NCI |
| Role: | Co-Shared Resource Director |
| ID: | P01CA06294 |
| Date: | 2010 - 2014 |
| Title: | Nanovectors Are Modular Platforms For Safe And Effective Targeted Therapy Of Head And Neck Cancer |
| Funding Source: | Rice University |
| Role: | PI |
| ID: | MDACC 30385 |
| Date: | 2010 - 2014 |
| Title: | Comprehensive Analysis of Genetic and Epigenetic Changes in Oral Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP100233 02 |
| Date: | 2010 - 2014 |
| Title: | Targeting c-Src in Head and Neck Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA143369 05 |
| Date: | 2009 - 2012 |
| Title: | Comprehensive Analysis of Genetic Alterations in Oral Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| ID: | 5 RC2 DE020958 03 |
| Date: | 2009 - 2014 |
| Title: | Critical Role of TrkB for Invasion and Metastasis of Oral Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | Co-Mentor |
| ID: | 5 K08 DE019185 05 |
| Date: | 2009 - 2018 |
| Title: | Progression and Metastasis of Oral Tongue Cancer |
| Funding Source: | NIH/NIDCR |
| Role: | PI |
| ID: | 5 R01 DE014613 13 |
| Date: | 2008 - 2013 |
| Title: | MD Anderson Cancer Center Head and Neck SPORE - Predictors of Resistance to Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer (PP3) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 P50 CA097007 10 |
| Date: | 2008 - 2013 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE - Developmental Research Program (DRP) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 P50 CA097007 10 |
| Date: | 2008 - 2015 |
| Title: | MD Anderson Cancer Center Head & Neck SPORE - Administrative Core (Core A) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 P50 CA097007 10 |
| Date: | 2008 - 2015 |
| Title: | M D Anderson Cancer Center Head & Neck SPORE - Career Development Program (CDP) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5P50CA097007-10 |
| Date: | 2008 - 2011 |
| Title: | The Medical NanoVector Research and Development Center of the Alliance for NanoHealth |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | W81XWH 07 2 0101 |
| Date: | 2008 - 2009 |
| Title: | The 7th International Conference on Head and Neck Cancer (SICHNCa) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R13 DE019081 |
| Date: | 2008 - 2013 |
| Title: | Training of Academic Surgical Oncologists |
| Funding Source: | NIH/NCI |
| Role: | Co-Mentor |
| ID: | 5 T32 CA009599 23 |
| Date: | 2006 - 2009 |
| Title: | Adenoid Cystic Carcinoma Organization International |
| Funding Source: | MDACC |
| Role: | PI |
| ID: | MDACC 26708 |
| Date: | 2005 - 2010 |
| Title: | Research Training in Otolaryngology-Head and Neck Surgery |
| Funding Source: | NIH/NIDCD |
| Role: | Co-I |
| ID: | 5T32DC007367-05 |
| Date: | 2003 - 2008 |
| Title: | UT-H Comprehensive Research Training Program in Craniofacial-Oral Biology |
| Funding Source: | NIH/NIDCR |
| Role: | Co-I |
| ID: | T32 DE15355 |
| Date: | 2002 - 2009 |
| Title: | MD Anderson Cancer Center SPORE in Head and Neck Cancer-Project 2 |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P50 CA97007 |
| Date: | 1998 - 2005 |
| Title: | Biochemoprevention Therapy in Advanced Laryngeal Dysplasia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01 CA079437 |
| Date: | 1995 - 2011 |
| Title: | Training of Academic Head and Neck Surgical Oncologist |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 T32 CA60374 15 |
| Date: | 1978 - 2009 |
| Title: | Cancer Center Support Grant - Central Media Laboratory |
| Funding Source: | NIH/NCI |
| Role: | Core Leader |
| ID: | P30 CA16672 |
Selected Publications
Peer-Reviewed Articles
- Peng, F, Sinjab, A, Dai, Y, Treekitkarnmongkol, W, Yang, S, Gomez Bolanos, L, Zhou, T, Chen, M, Serrano, A, Krishna, A, Karimi, N, Sharma, M, Basi, A, Pei, G, Liao, J, Liu, Y, Feng, J, Rahal, Z, Liu, Y, Jiang, J, Yu, K, Noun, T, Liu, Y, Khan, KB, Cho, KS, Chen, J, Solis Soto, LM, Mazzilli, SA, Dubinett, SM, Cascone, T, Spira, A, Swisher, SG, Jimbo, N, Hayashi, T, Kishikawa, S, Takamochi, K, Itoh, T, Yao, T, Suzuki, K, Kalhor, N, Wistuba, II, Li, M, Moghaddam, SM, Fujimoto, J, Burks, JK, Myers, JN, Akdemir, KC, Wang, L, Kadara, HN. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer cell 44(2):321-339.e13, 2026. e-Pub 2026. PMID: 41202811.
- Trinconi Cunha, M, Sewastjanow-Silva, M, Holsinger, F, Garden, AS, El-Naggar, AK, Myers, JN, Lewin, JS, Gillenwater, AM, Lee, JJ, Khuri, F, Diaz Jr, EM, Ferrarotto, R. Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma. Cancer 131(23), 2025. e-Pub 2025. PMID: 41250807.
- Gencel-Augusto J, Li H, Woerner LC, Tian N, Borah AA, Myers JN, Ha P, Johnson DE, Grandis JR. Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC. Head Neck, 2025. e-Pub 2025. PMID: 41168931.
- Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer 133(12):1802-1814, 2025. e-Pub 2025. PMID: 41053162.
- Patel R, Saab K, Luo L, Ma Y, Osman RA, Williams NT, Everitt J, Zelazowski MJ, Castro P, Decker WK, Hudson WH, Myers JN, Sandulache VC, Frederick MJ, Mowery YM, Kirsch DG. Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31(19):4184-4195, 2025. e-Pub 2025. PMID: 40742317.
- Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Nikpoor AR, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallon de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Goepfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature 646(8084):462-473, 2025. e-Pub 2025. PMID: 40836096.
- Moreno AC, Watson EE, Humbert-Vidan L, Peterson DE, van Dijk LV, Urbano TG, Bosch LVD, Hope AJ, Katz MS, Hoebers FJP, Wesson RAA, Bates JE, Bossi P, Dayo AF, Dore M, Fregnani ER, Galloway TJ, Gelblum DY, Hanna IA, Henson CE, Kiat-Amnuay S, Korfage A, Lee NY, Lewis CM, Lynggaard CD, Makitie AA, Magalhaes M, Mowery YM, Munoz-Montplet C, Myers JN, Orlandi E, Patel J, Rigert JM, Saunders D, Schoenfeld JD, Selek U, Somay E, Takiar V, Thariat J, Verduijn GM, Villa A, West NS, Witjes MJH, Won AM, Wong ME, Yao CMKL, Young SW, Al-Eryani K, Barbon CEA, Buurman DJM, Dieleman FJ, Hofstede TM, Khan AA, Otun AO, Robinson JC, Hum L, Johansen J, Lalla R, Lin A, Patel V, Shaw RJ, Chambers MS, Ma D, Singh M, Yarom N, Mohamed ASR, Hutcheson KA, Lai SY, Fuller CD. International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Interdisciplinary Modified Delphi Study. Int J Radiat Oncol Biol Phys 122(2):341-354, 2025. e-Pub 2025. PMID: 39826846.
- Kawabe M, Yang S, Bolanos LG, Takamatsu S, Flores S, Castro PD, Tsai TY, Nishikawa-Kaga A, Frederick MJ, Sandulache V, Kadara H, Myers JN, Osman AA. Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. bioRxiv, 2025. e-Pub 2025. PMID: 40501947.
- Gencel-Augusto J, Li H, Woerner LC, Borah AA, Myers JN, Ha P, Johnson DE, Grandis JR. Human Papilloma Virus does not fully inactivate p53 cellular activity in HNSCC. bioRxiv, 2025. e-Pub 2025. PMID: 41031015.
- Li Y, Yadollahi P, Essien FN, Putluri V, Ambati CSR, Kami Reddy KR, Kamal AHM, Putluri N, Abdurrahman LM, Ruiz Echartea ME, Ernste KJ, Trivedi AJ, Vazquez-Perez J, Hudson WH, Decker WK, Patel R, Osman AA, Kheradmand F, Lai SY, Myers JN, Skinner HD, Coarfa C, Lee K, Jain A, Malovannaya A, Frederick MJ, Sandulache VC. Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. J Transl Med 23(1):403, 2025. e-Pub 2025. PMID: 40188338.
- Sahin O, Kamel S, Wahid KA, Dede C, Taku N, He R, Naser MA, Sharafi CS, Makitie A, Kann BH, Kaski K, Sahlsten J, Jaskari J, Amit M, Chronowski GM, Diaz EM Jr, Garden AS, Goepfert RP, Guenette JP, Gunn GB, Hirvonen J, Hoebers F, Hutcheson KA, Guha-Thakurta N, Johnson J, Kaya D, Khanpara SD, Nyman K, Lai SY, Lango M, Learned KO, Lee A, Lewis CM, Maniakas A, Moreno AC, Myers JN, Phan J, Pytynia KB, Rosenthal DI, Sandulache VC, Schellingerhout D, Shah SJ, Sikora AG, Mohamed ASR, Chen MM, Fuller CD. International multispecialty expert physician preoperative identification of extranodal extension in patients with oropharyngeal cancer using computed tomography: Prospective blinded human inter-observer performance evaluation. Cancer 131(7):e35815, 2025. e-Pub 2025. PMID: 40159431.
- Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. bioRxiv, 2025. e-Pub 2025. PMID: 39868226.
- Li Y, Yadollahi P, Essien F, Putluri V, Chandra S, Kami Reddy KR, Kamal A, Putluri N, Abdurrahman LM, Ruiz-Echartea E, Ernste K, Trivedi A, Vazquez-Perez J, Hudson WH, Decker W, Patel R, Osman AA, Kheradmand F, Lai SY, Myers JN, Skinner HD, Coarfa C, Lee K, Jain A, Malovannaya A, Frederick MJ, Sandulache VC. Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. bioRxiv, 2024. e-Pub 2024. PMID: 39484602.
- Working Group MOCEEA, Sahin O, Kamel S, Wahid KA, Dede C, Taku N, He R, Naser MA, Sharafi S, Mäkitie A, Kann BH, Kaski K, Sahlsten J, Jaskari J, Amit M, Chronowski GM, Diaz EM, Garden AS, Goepfert RP, Guenette JP, Gunn GB, Hirvonen J, Hoebers F, Hutcheson KA, Guha-Thakurta N, Johnson J, Kaya D, Khanpara SD, Nyman K, Lai SY, Lango M, Learned KO, Lee A, Lewis CM, Maniakas A, Moreno AC, Myers JN, Phan J, Pytynia KB, Rosenthal DI, Sandulache VC, Schellingerhout D, Shah SJ, Sikora AG, Mohamed ASR, Chen MM, Fuller CD. Multi-Specialty Expert Physician Identification of Extranodal Extension in Computed Tomography Scans of Oropharyngeal Cancer Patients: Prospective Blinded Human Inter-Observer Performance Evaluation. medRxiv, 2024. e-Pub 2024. PMID: 36865096.
- Michikawa C, Gleber-Netto FO, Pickering CR, Rao X, Wang J, Sikora AG, Myers JN, Frederick MJ. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncol 153:106729, 2024. e-Pub 2024. PMID: 38663156.
- Anderson BJ, Moreno AC, Qing Y, Lee JJ, Johnson FM, Lango MN, Barbon CEA, Tripuraneni L, Sahli A, Piper V, Gross N, Fuller CD, Lai SY, Myers JN, Hutcheson KA. Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6-Year Prospective Registry Analysis. Otolaryngol Head Neck Surg 170(5):1319-1330, 2024. e-Pub 2024. PMID: 38353360.
- Carlander AF, Bendtsen SK, Rasmussen JH, Jakobsen KK, Garset-Zamani M, Grønhøj C, Friborg J, Hutcheson K, Johnson FM, Fuller CD, Moreno AC, Babarinde T, Gross ND, Myers JN, von Buchwald C. Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas. Eur J Cancer 202:113983, 2024. e-Pub 2024. PMID: 38452723.
- Ayala-Orozco C, Galvez-Aranda D, Corona A, Seminario JM, Rangel R, Myers JN, Tour JM. Molecular jackhammers eradicate cancer cells by vibronic-driven action. Nat Chem 16(3):456-465, 2024. e-Pub 2024. PMID: 38114816.
- Contrera KJ, Hassan AM, Shuck JW, Bobian M, Ha AY, Chang EI, Garvey PB, Roubaud MS, Lee ZH, Hanasono MM, Gross ND, Myers JN, Yu P, Largo RD. Outcomes for 160 Consecutive Lateral Arm Free Flaps for Head and Neck Reconstruction. Otolaryngol Head Neck Surg 170(3):747-757, 2024. e-Pub 2024. PMID: 38037485.
- Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, Beadle B, Molkentine D, Molkentine J, Dhawan A, Abdelhakiem M, Osman AA, Leibowitz BJ, Myers JN, Pickering CR, Sandulache VC, Heymach J, Skinner HD. FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner. Clin Cancer Res 30(1):187-197, 2024. e-Pub 2024. PMID: 37819945.
- Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
- Na’ara, S, Yaniv, D, Andrews, C, Sathishkumar, HN, Guimaraes de Sousa, L, Akhave, NS, Williams, MD, Myers, JN, Chambers, MS, Amit, M. Intralesional nivolumab in oral potentially malignant disorders. Journal of Clinical Oncology 42(16_suppl):6016, 2024. e-Pub 2024.
- Ferrarotto R, Nagarajan P, Maronge JM, Johnson JM, Rosenthal DI, Myers JN, Gross ND. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol Head Neck Surg 149(9):847-849, 2023. e-Pub 2023. PMID: 37535378.
- Shi Y, Ren X, Cao S, Chen X, Yuan B, Brasil da Costa FH, Rodriguez Rosario AE, Corona A, Michikawa C, Veeramachaneni R, Osman AA, Xie T, Wang W, Sikora AG, Myers JN, Rangel R. TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37604640.
- Zhang X, Gleber-Netto FO, Wang S, Jin KW, Yang DM, Gillenwater AM, Myers JN, Ferrarotto R, Pickering CR, Xiao G. A Deep Learning Onion Peeling Approach to Measure Oral Epithelium Layer Number. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568707.
- Baruch, EN, Nagarajan, P, Gleber-Netto, FO, Rao, X, Xie, T, Akhter, S, Adewale, A, Shajedul, I, Mattson, BJ, Ferrarotto, R, Wong, MK, Davies, MA, Jindal, S, Basu, S, Harwood, C, Leigh, I, Ajami, NJ, Futreal, A, Castillo, M, Gunaratne, PH, Goepfert, RP, Khushalani, N, Wang, J, Watowich, SS, Calin, GA, Migden, MR, Vermeer, PD, D'Silva, NJ, Yaniv, D, Burks, JK, Gomez, JA, Dougherty, PM, Tsai, KY, Allison, JP, Sharma, P, Wargo, J, Myers, JN, Gross, N, Amit, M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Research square, 2023. e-Pub 2023. PMID: 37503252.
- Chen HY, Zhao W, Na'ara S, Gleber-Netto FO, Xie T, Ali S, Thompson ZM, Buell J, Stafford H, Nagarajan P, Davies M, Wong MK, Migden MR, Sharma P, Myers JN, Gross ND, Amit M. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol 7:e2200490, 2023. e-Pub 2023. PMID: 37285560.
- Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, Skinner HD, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer 128(11):2013-2024, 2023. e-Pub 2023. PMID: 37012319.
- Contrera KJ, Tam S, Pytynia K, Diaz EM, Hessel AC, Goepfert RP, Lango M, Su SY, Myers JN, Weber RS, Eguia A, Pisters PWT, Adair DK, Nair AS, Rosenthal DI, Mayo L, Chronowski GM, Zafereo ME, Shah SJ. ASO Visual Abstract: Impact of Cancer Care Regionalization on Patient Volume. Ann Surg Oncol 30(4):2341-2342, 2023. e-Pub 2023. PMID: 36720835.
- Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, Yu W, Sandulache V, Ma W, Shen L, Wang J, Singh AK, Frederick MJ, Spencer ND, Kovacs J, Heffernan T, Symmans WF, Rai K, Myers JN. Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 29(7):1344-1359, 2023. e-Pub 2023. PMID: 36689560.
- Contrera KJ, Tam S, Pytynia K, Diaz EM, Hessel AC, Goepfert RP, Lango M, Su SY, Myers JN, Weber RS, Eguia A, Pisters PWT, Adair DK, Nair AS, Rosenthal DI, Mayo L, Chronowski GM, Zafereo ME, Shah SJ. Impact of Cancer Care Regionalization on Patient Volume. Ann Surg Oncol 30(4):2331-2338, 2023. e-Pub 2022. PMID: 36581726.
- William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer 129(5):714-727, 2023. e-Pub 2023. PMID: 36597662.
- Zhang X, Gleber-Netto FO, Wang S, Martins-Chaves RR, Gomez RS, Vigneswaran N, Sarkar A, William WN, Papadimitrakopoulou V, Williams M, Bell D, Palsgrove D, Bishop J, Heymach JV, Gillenwater AM, Myers JN, Ferrarotto R, Lippman SM, Pickering CR, Xiao G. Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med. e-Pub 2023. PMID: 36721313.
- Coleman, N, Marcelo, KL, Hopkins, JF, Khan, NI, Du, R, Hong, L, Park, E, Balsara, B, Leoni, M, Pickering, CR, Myers, JN, Heymach, JV, Albacker, LA, Hong, DS, Gillison, M, Le, X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology 7, 2023. e-Pub 2023. PMID: 36603172.
- Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst 114(12):1619-1627, 2022. e-Pub 2022. PMID: 36053203.
- Contrera KJ, Zafereo ME, Yaniv D, Roberts DB, Gillenwater AM, Hanna EY, Weber RS, Myers JN, Chang EI, Garvey PB, Hanasono MM, Yu P, Hutcheson KA, Fuller CD, Tyler MA, Neskey DM. Outcomes for recurrent oral cavity squamous cell carcinoma. Oral Oncol 134:106127, 2022. e-Pub 2022. PMID: 36155359.
- Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Shah PA, Pickering CR, Myers JN, Wang J, Frederick MJ, Johnson FM. Combined TRIP13 and Aurora kinase inhibition induces apoptosis in human papillomavirus-driven cancers. Clin Cancer Res 28(20):4479-4493, 2022. e-Pub 2022. PMID: 35972731.
- Contrera KJ, Huang AT, Shenson JA, Tang C, Roberts D, Myers JN, Weber RS, Lai SY, Williams M, El-Hallal M, Jacob D, Zafereo M. Primary and recurrent regional metastases for lateralized oral cavity squamous cell carcinoma. Surg Oncol 44:101804, 2022. e-Pub 2022. PMID: 35932620.
- Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 31:100813, 2022. e-Pub 2022. PMID: 35834946.
- Farah M, Milton DR, Gross ND, Nagarajan P, Gu J, Curry JL, Ivan D, Torres-Cabala CA, Myers JN, Prieto VG, Aung PP. Histopathologic Features Predictive of Metastasis and Survival in 230 Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck and Non–Head and Neck Locations: A Single-Center Retrospective Study. J Eur Acad Dermatol Venereol 36(8):1246-1255, 2022. e-Pub 2022. PMID: 35426183.
- Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B, Gleber-Netto FO, Tian X, Rodriguez-Rosario AE, Osman AA, Wang J, Pickering CR, Ren X, Sikora AG, Myers JN, Rangel R. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol 5(1):757, 2022. e-Pub 2022. PMID: 35902768.
- Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res 28(13):2796-2806, 2022. e-Pub 2022. PMID: 35443062.
- Contrera KJ, Chinn SB, Weber RS, Roberts D, Myers JN, Lai SY, Lewis CM, Hessel AC, Gillenwater AM, Mulcahy CF, Yu P, Hanasono MM, Fuller CD, Chambers MS, Zafereo ME. Outcomes after definitive surgery for mandibular osteoradionecrosis. Head Neck 44(6):1313-1323, 2022. e-Pub 2022. PMID: 35238096.
- Hsu TK, Asmussen J, Koire A, Choi BK, Gadhikar MA, Huh E, Lin CH, Konecki DM, Kim YW, Pickering CR, Kimmel M, Donehower LA, Frederick MJ, Myers JN, Katsonis P, Lichtarge O. A general calculus of fitness landscapes finds genes under selection in cancers. Genome Res 32(5):916-929, 2022. e-Pub 2022. PMID: 35301263.
- Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 28(8):1735, 2022. e-Pub 2022. PMID: 35419587.
- Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, Skinner HD, Pickering CR, Myers JN, Rai K. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol 10:936168, 2022. e-Pub 2022. PMID: 35927986.
- Michikawa C, Torres-Saavedra PA, Silver NL, Harari PM, Kies MS, Rosenthal DI, Le QT, Jordan RC, Duose DY, Mallampati S, Trivedi S, Luthra R, Wistuba II, Osman AA, Lichtarge O, Foote RL, Parvathaneni U, Hayes DN, Pickering CR, Myers JN. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol 7(6):100989, 2022. e-Pub 2022. PMID: 36420184.
- Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 127(23):4413-4420, 2021. e-Pub 2021. PMID: 34358340.
- Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun 12(1):6340, 2021. e-Pub 2021. PMID: 34732714.
- Gorur A, Patiño M, Shi T, Corrales G, Takahashi H, Rangel R, Gleber-Netto FO, Pickering C, Myers JN, Cata JP. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. J Cell Physiol 236(11):7698-7710, 2021. e-Pub 2021. PMID: 34038587.
- Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
- Guo TW, Saiyed F, CMKL Y, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer 127(16):2916-2925, 2021. e-Pub 2021. PMID: 33873251.
- Gorur A, Patiño M, Takahashi H, Corrales G, Pickering CR, Gleber-Netto FO, Myers JN, Cata JP. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci 278:119541, 2021. e-Pub 2021. PMID: 33930368.
- Shi Y, Xie TX, Leach DG, Wang B, Young S, Osman AA, Sikora AG, Ren X, Hartgerink JD, Myers JN, Rangel R. Local anti-PD-1 delivery prevents progression of premalignant lesions in a 4NQO-oral carcinogenesis mouse model. Cancer Prev Res (Phila) 14(8):767-778, 2021. e-Pub 2021. PMID: 34021022.
- van Dijk LV, Mohamed ASR, Ferrarotto R, McCoy LA, Sharafi CS, Jones E, Steele K, Moreno AC, Lai SY, Garden AS, Myers JN, Rosenthal DI, Fuller CD, Hutcheson KA, Group MD. The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. Cancer 127(14):2453-2464, 2021. e-Pub 2021. PMID: 33788956.
- Lindemann A, Patel AA, Tang L, Tanaka N, Gleber-Netto FO, Bartels MD, Wang L, McGrail DJ, Lin SY, Frank SJ, Frederick MJ, Myers JN, Osman AA. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther 20(7):1257-1269, 2021. e-Pub 2021. PMID: 33947685.
- Saiyed FK, Guo T, Johnson F, Myers JN. Characterizing Distant Metastases and Survival in Oropharyngeal Squamous Cell Carcinoma. Head Neck 43(7):2101-2109, 2021. e-Pub 2021. PMID: 33738875.
- Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. Retraction Note to: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 124(10):1747, 2021. e-Pub 2021. PMID: 33603199.
- Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
- Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer 127(8):1238-1245, 2021. e-Pub 2021. PMID: 33320343.
- Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN, Caulin C. Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33806894.
- Silverman DA, Martinez VK, Dougherty PM, Myers JN, Calin GA, Amit M. Cancer-associated neurogenesis and nerve-cancer crosstalk. Cancer Res 81(6):1431-1440, 2021. e-Pub 2021. PMID: 33334813.
- Monteiro de Oliveira Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, McArthur MJ, Bell D, William WN, Heymach JV. Targeting of CD40 and PD-L1 pathways inhibit progression of oral premalignant lesions in a carcinogen-induced model of oral squamous cell carcinoma. Cancer Prev Res (Phila) 14(3):313-324, 2021. e-Pub 2021. PMID: 33277316.
- Campbell BR, Chen Z, Faden DL, Agrawal N, Li RJ, Hanna GJ, Iyer NG, Boot A, Rozen SG, Vettore AL, Panda B, Krishnan NM, Pickering CR, Myers JN, Guo X, Lang Kuhs KA. The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma. Cancer 127(4):544-553, 2021. e-Pub 2020. PMID: 33146897.
- Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer 144:169-177, 2021. e-Pub 2021. PMID: 33352413.
- Srivastava, A, Maniakas, A, Myers, JN, Chambers, MS, Cardoso, R. Reconstruction of intraoral oncologic surgical defects with Integra® bilayer wound matrix. Clinical Case Reports 9(1):213-219, 2021. e-Pub 2021. PMID: 33489162.
- Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, Clump DA, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, Skinner HD. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol 97(8):1121-1128, 2021. e-Pub 2021. PMID: 32073931.
- Wang L, Fossati P, Paganetti H, Ma L, Gillison M, Myers JN, Hug E, Frank SJ. The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Int J Part Ther 8(1):3-13, 2021. e-Pub 2021. PMID: 34285931.
- Gunn GB, Garden AS, Ye R, Ausat N, Dahlstrom KR, Morrison WH, Fuller CD, Phan J, Reddy JP, Shah SJ, Mayo LL, Chun SG, Chronowski GM, Moreno AC, Myers JN, Hanna EY, Esmaeli B, Gillison ML, Ferrarotto R, Hutcheson KA, Chambers MS, Ginsberg LE, El-Naggar AK, Rosenthal DI, Zhu XR, Frank SJ. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther 8(1):108-118, 2021. e-Pub 2021. PMID: 34285940.
- Uzunparmak B, Gao M, Lindemann A, Erikson K, Wang L, Lin E, Frank SJ, Gleber-Netto FO, Zhao M, Skinner HD, Newton J, Sikora AG, Myers JN, Pickering CR. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight 5(23), 2020. e-Pub 2020. PMID: 33108350.
- Boukovalas S, Goepfert RP, Smith JM, Mecham E, Liu J, Zafereo ME, Chang EI, Hessel AC, Hanasono MM, Gross ND, Yu P, Lewin JS, Lewis CM, Diaz EM, Weber RS, Myers JN, Offodile AC. Association between postoperative complications and long-term oncologic outcomes following total laryngectomy: 10-year experience at MD Anderson Cancer Center. Cancer 126(22):4905-4916, 2020. e-Pub 2020. PMID: 32931057.
- Gleber-Netto FO, Neskey D, Costa AFM, Kataria P, Rao X, Wang J, Kowalski LP, Pickering CR, Dias-Neto E, Myers JN. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer 126(20):4498-4510, 2020. e-Pub 2020. PMID: 32797678.
- Wang L, Cao J, Wang X, Lin E, Wang Z, Li Y, Li Y, Chen M, Wang X, Jiang B, Zhang R, Sahoo N, Zhang X, Zhu XR, Myers JN, Frank SJ. Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells. Head Neck 42(9):2244-2256, 2020. e-Pub 2020. PMID: 32323895.
- Head MD, Guidelines Consortium NST, members C, Maniakas A, Jozaghi Y, Zafereo ME, Sturgis EM, Su SY, Gillenwater AM, Gidley PW, Lewis CM, Diaz E, Goepfert RP, Kupferman ME, Gross ND, Hessel AC, Pytynia KB, Nader ME, Wang JR, Lango MN, Kiong KL, Guo T, Zhao X, CMKL Y, Appelbaum E, Alpard J, Garcia JA, Terry S, Flynn JE, Bauer S, Fournier D, Burgess CG, Wideman C, Johnston M, You C, De Luna R, Joseph L, Diersing J, Prescott K, Heiberger K, Mugartegui L, Rodriguez J, Zendehdel S, Sellers J, Friddell RA, Thomas A, Khanjae SJ, Schwarzlose KB, Chambers MS, Hofstede TM, Cardoso RC, Wesson RA, Won A, Otun AO, Gombos DS, Al-Zubidi N, Hutcheson KA, Gunn GB, Rosenthal DI, Gillison ML, Ferrarotto R, Weber RS, Hanna EY, Myers JN, Lai SY. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck 42(6):1194-1201, 2020. e-Pub 2020. PMID: 32342541.
- Kiong KL, Guo T, CMKL Y, Gross ND, Hanasono MM, Ferrarotto R, Rosenthal DI, Myers JN, Hanna EY, Lai SY. Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck 42(6):1179-1186, 2020. e-Pub 2020. PMID: 32459061.
- Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman Karagiannis DT, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora A, Gillison ML, Glisson BS, Gross ND. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clin Cancer Res. e-Pub 2020. PMID: 32269052.
- Chari NS, Ivan C, Le X, Li J, Mijiti A, Patel AA, Osman AA, Peterson CB, Williams MD, Pickering CR, Caulin C, Myers JN, Calin GA, Lai SY. Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer. J Natl Cancer Inst 112(3):266-277, 2020. e-Pub 2020. PMID: 31124563.
- Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature 578(7795):449-454, 2020. e-Pub 2020. PMID: 32051587.
- Wang L, Yang L, Han S, Zhu J, Li Y, Wang Z, Fan YH, Lin E, Zhang R, Sahoo N, Li Y, Zhang X, Wang X, Li T, Zhu XR, Zhu H, Heymach JV, Myers JN, Frank SJ. Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. Head Neck 42(2):289-301, 2020. e-Pub 2020. PMID: 31710172.
- Tam S, Yao CMK, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. e-Pub 2019. PMID: 31804658.
- Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res 25(18):5650-5662, 2019. e-Pub 2019. PMID: 31308060.
- Takahashi Y, Gleber-Netto FO, Bell D, Roberts D, Xie TX, Abdelmeguid AS, Pickering C, Myers JN, Hanna EY. Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma. Oral Oncol 97:56-61. e-Pub 2019. PMID: 31421472.
- Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 25(15):4861, 2019. e-Pub 2019. PMID: 31371311.
- Takahashi Y, Gleber-Netto FO, Bell D, Roberts D, Xie TX, Abdelmeguid AS, Pickering C, Myers JN, Hanna EY. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head Neck 41(8):2688-2695, 2019. e-Pub 2019. PMID: 30932264.
- Bell AH, Prieto VG, Ferrarotto R, Goepfert RP, Myers JN, Weber R, Bell D. Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. Ann Diagn Pathol 41:14-23, 2019. e-Pub 2019. PMID: 31128548.
- Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clin Cancer Res 25(11):3329-3340, 2019. e-Pub 2019. PMID: 30770351.
- Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol 46(2):152-158, 2019. e-Pub 2019. PMID: 30414196.
- Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4(1). e-Pub 2019. PMID: 30626753.
- Wang L, Han S, Zhu J, Wang X, Li Y, Wang Z, Lin E, Wang X, Molkentine DP, Blanchard P, Yang Y, Zhang R, Sahoo N, Gillin M, Zhu XR, Zhang X, Myers JN, Frank SJ. Proton versus photon radiation-induced cell death in head and neck cancer cells. Head Neck 41(1):46-55, 2019. e-Pub 2019. PMID: 30561022.
- Tanaka N, Osman AA, Takahashi Y, Lindemann A, Patel AA, Zhao M, Takahashi H, Myers JN. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol 87:49-57, 2018. e-Pub 2018. PMID: 30527243.
- Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett 431:64-72, 2018. e-Pub 2018. PMID: 29807113.
- Ma J, Fu Y, Tu YY, Liu Y, Tan YR, Ju WT, Pickering CR, Myers JN, Zhang ZY, Zhong LP. Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer 18(1):758, 2018. e-Pub 2018. PMID: 30041611.
- Lindemann A, Takahashi H, Patel AA, Osman AA, Myers JN. Targeting the DNA Damage Response in OSCC with TP53 Mutations. J Dent Res 97(6):635-644, 2018. e-Pub 2018. PMID: 29489434.
- Schaverien MV, Dean RA, Myers JN, Fang L, Largo RD, Yu P. Outcomes of microvascular flap reconstruction of the head and neck in patients receiving systemic immunosuppressive therapy for organ transplantation. J Surg Oncol 117(7):1575-1583, 2018. e-Pub 2018. PMID: 29723399.
- Lam-Ubol A, Fitzgerald AL, Ritdej A, Phonyiam T, Zhang H, Myers JN, Huang P, Trachootham D. Sensory acceptable equivalent doses of β-phenylethyl isothiocyanate (PEITC) induce cell cycle Arrest and Retard the Growth of p53 Mutated Oral Cancer in Vitro and in Vivo. Royal Society of Chemistry - Food and Function 9(7):3640-3656, 2018. e-Pub 2018.
- Sandulache VC, Michikawa C, Kataria P, Gleber-Netto FO, Bell D, Trivedi S, Rao X, Wang J, Zhao M, Jasser S, Myers JN, Pickering CR. High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res 24(7):1727-1733, 2018. e-Pub 2018. PMID: 29330202.
- Abram TJ, Pickering CR, Lang AK, Bass NE, Raja R, Meena C, Alousi AM, Myers JN, McDevitt JT, Gillenwater AM, Vigneswaran N. Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. Transl Oncol 11(2):477-486, 2018. e-Pub 2018. PMID: 29481998.
- Tanaka N, Zhao M, Tang L, Patel AA, Xi Q, Van HT, Takahashi H, Osman AA, Zhang J, Wang J, Myers JN, Zhou G. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene 37(10):1279-1292, 2018. e-Pub 2018. PMID: 29269868.
- Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78(3):781-797, 2018. e-Pub 2018. PMID: 29229598.
- Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, Head, Supplement Consortium NCSPOREHIV. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124(1):84-94, 2018. e-Pub 2018. PMID: 29053175.
- Myers JN. The Next 19 Years of the American Head and Neck Society. JAMA Otolaryngol Head Neck Surg 143(12):1255-1259, 2017. e-Pub 2017. PMID: 29121199.
- Wang J, Xie T, Wang B, William WN, Heymach JV, El-Naggar AK, Myers JN, Caulin C. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. Cancer Prev Res (Phila) 10(12):684-693, 2017. e-Pub 2017. PMID: 29018057.
- Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation. Clin Cancer Res 23(21):6541-6554, 2017. e-Pub 2017. PMID: 28790110.
- Narayan P, Doumas M, Kumar A, Faselis CJ, Myers JN, Pittaras A, Kokkinos PF. Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. Am J Cardiol 120(9):1568-1571, 2017. e-Pub 2017. PMID: 28886854.
- Faden DL, Thomas S, Cantalupo PG, Agrawal N, Myers J, DeRisi J. Multimodality Analysis Supports APOBEC as a Major Source of Mutations in Head and Neck Squamous Cell Carcinoma. Oral Oncology 74:8-14, 2017. e-Pub 2017.
- Kalu NN, Mazumdar T, Peng S, Shen I, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 2017. e-Pub 2017.
- Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun 8(1):465, 2017. e-Pub 2017. PMID: 28878238.
- Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol 72:90-97, 2017. e-Pub 2017. PMID: 28797467.
- Schvartsman G, Perez K, Flynn JE, Myers JN, Tawbi H. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. Journal for ImmunoTherapy of Cancer, 2017. e-Pub 2017.
- Chang KP, Wang CI, Pickering CR, Huang Y, Tsai CN, Tsang NM, Kao HK, Cheng MH, Myers JN. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck 39(6):1131-1137, 2017. e-Pub 2017. PMID: 28230921.
- Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. e-Pub 2017. PMID: 28476872.
- Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, Sawakuma K, Takada K, Oikawa R, Watanabe Y, Yamamoto H, Itoh F, Myers JN, Oridate N. Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer 140(7):1571-1580, 2017. e-Pub 2017. PMID: 28006857.
- Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck 39(4):633-638, 2017. e-Pub 2017. PMID: 28006086.
- Coaxum SD, Tiedeken J, Garrett-Mayer, E, Myers JN, Rosenzweig SA, Neskey DM. The tumor suppressor capability of p53 is dependent on Non-muscle Myosin IIA function in Head and Neck Cancer. Oncotarget 8(14):22991-23007, 2017. e-Pub 2017. PMID: 28160562.
- Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2017. e-Pub 2017. PMID: 28196595.
- Sandulache VC, Chen Y, Feng L, William WN, Skinner HD, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY. Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget. e-Pub 2017. PMID: 28184025.
- Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu N, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. e-Pub 2017. PMID: 28126323.
- Nader ME, Myers JN, Gidley PW. Sudden hearing loss in a melanoma patient on pembrolizumab: An Etiology not to be omitted in the differential diagnosis. J Immunother Cancer 5:24, 2017. e-Pub 2017. PMID: 28331614.
- Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. J Cell Biochem 117(12):2682-2692, 2016. e-Pub 2016. PMID: 27166782.
- Wang L, Wang X, Li Y, Han S, Zhu J, Wang X, Molkentine DP, Blanchard P, Yang Y, Zhang R, Sahoo N, Gillin M, Zhu XR, Zhang X, Myers JN, Frank SJ. Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. Head Neck. e-Pub 2016. PMID: 28039958.
- Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol. e-Pub 2016. PMID: 27775232.
- Ma N, Jiang YW, Zhang X, Wu H, Myers JN, Liu P, Jin H, Gu N, He N, Wu FG, Chen Z. Enhanced Radiosensitization of Gold Nanospikes via Hyperthermia in Combined Cancer Radiation and Photothermal Therapy. ACS Appl Mater Interfaces. e-Pub 2016. PMID: 27689441.
- Saluja K, Rao PH, Myers JN, El-Naggar AK. Novel t(1;3)(q21,p21) translocation in a basal cell adenocarcinoma of the parotid gland: potential association with tumorigenesis. Hum Pathol 54:189-92, 2016. e-Pub 2016. PMID: 27085552.
- Li Z, Gonzalez CL, Wang B, Zhang Y, Mejia O, Katsonis P, Lichtarge O, Myers JN, El-Naggar AK, Caulin C. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H). J Pathol. e-Pub 2016. PMID: 27447534.
- Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer. Clin Cancer Res. e-Pub 2016. PMID: 27036135.
- Takahashi Y, Lee J, Pickering C, Bell D, Jiffar TW, Myers JN, Hanna EY, Kupferman ME. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. e-Pub 2016. PMID: 26752332.
- Hyakusoku H, Sano D, Takahashi H, Hatano T, Isono Y, Shimada S, Ito Y, Myers JN, Oridate N. JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma. J Exp Clin Cancer Res 35(1):6, 2016. e-Pub 2016. PMID: 26754630.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Sandulache VC, Chen Y, Skinner HD, Lu T, Feng L, Court LE, Myers JN, Meyn RE, Fuller CD, Bankson JA, Lai SY. Acute tumor lactate perturbations as a biomarker of genotoxic stress: development of a biochemical model. Mol Cancer Ther 14(12):2901-8, 2015. e-Pub 2015. PMID: 26376962.
- William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol:1-8. e-Pub 2015. PMID: 26540028.
- Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila) 8(11):1027-35, 2015. e-Pub 2015. PMID: 26342026.
- Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA. Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins. Clin Cancer Res 21(21):4831-44, 2015. e-Pub 2015. PMID: 26124202.
- Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs 26(8):835-42, 2015. e-Pub 2015. PMID: 26053277.
- Monroe MM, Pattisapu P, Myers JN, Kupferman ME. Sentinel Lymph Node Biopsy Provides Prognostic Value in Thick Head and Neck Melanoma. Otolaryngol Head Neck Surg 153(3):372-8, 2015. e-Pub 2015. PMID: 26070510.
- Davis-Malesevich MV, Goepfert R, Kubik M, Roberts DB, Myers JN, Kupferman ME. Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy. Head Neck 37(8):1116-21, 2015. e-Pub 2015. PMID: 24764188.
- Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 7(293):293ra104, 2015. e-Pub 2015. PMID: 26109104.
- Woo SH, Yang LP, Chuang HC, Fitzgerald A, Lee HY, Pickering C, Myers JN, Skinner HD. Down-regulation of malic enzyme 1 & 2 sensitizes head and neck squamous cell carcinoma cells to therapy-induced senescence. Head Neck. e-Pub 2015. PMID: 25994759.
- Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res 75(7):1527-36, 2015. e-Pub 2015. PMID: 25634208.
- Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants (EAp53) is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res 75(7):1205-15, 2015. e-Pub 2015. PMID: 25691460.
- Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN. Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Head and Neck Cancer through Mito tic Arrest Followed by Senescence. Mol Cancer Ther 14(2):608-19, 2015. e-Pub 2015. PMID: 25504633.
- Hayes DN, Hrad TT, Network, Myers JN. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature:576-82. e-Pub 2015. PMID: 25631445.
- Fitzgerald AL, Osman AA, Xie TX, Patel A, Skinner H, Sandulache V, Myers JN. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis 6:e1678, 2015. e-Pub 2015. PMID: 25766317.
- Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20(24):6582-92, 2014. e-Pub 2014. PMID: 25303977.
- Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther 13(11):2738-50, 2014. e-Pub 2014. PMID: 25193510.
- Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck 36(11):1547-54, 2014. e-Pub 2014. PMID: 24123531.
- Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. e-Pub 2014. PMID: 25352401.
- Luke GP, Myers JN, Emelianov SY, Sokolov KV. Sentinel lymph node biopsy revisited: ultrasound-guided photoacoustic detection of micrometastases using molecularly targeted plasmonic nanosensors. Cancer Res 74(19):5397-408, 2014. e-Pub 2014. PMID: 25106426.
- Hauff SJ, Raju SC, Orosco RK, Gross AM, Diaz-Perez JA, Savariar E, Nashi N, Hasselman J, Whitney M, Myers JN, Lippman SM, Tsien RY, Ideker T, Nguyen QT. Matrix-Metalloproteinases in Head and Neck Carcinoma-Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice. Otolaryngol Head Neck Surg 151(4):612-8, 2014. e-Pub 2014. PMID: 25091190.
- Takahashi Y, Bell D, Agarwal G, Roberts D, Xie TX, El-Naggar A, Myers JN, Hanna EY. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck 36(8):1094-102, 2014. e-Pub 2014. PMID: 23836481.
- Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 32(23):2486-95, 2014. e-Pub 2014. PMID: 25002723.
- Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, Ward A, Tsai CJ, Ortega Alves MV, Zhou JH, Drummond J, El-Naggar AK, Gibbs R, Weinstein JN, Wheeler DA, Wang J, Frederick MJ, Myers JN. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res 20(14):3842-8, 2014. e-Pub 2014. PMID: 24874835.
- Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 36(7):1039-43, 2014. e-Pub 2014. PMID: 23784886.
- Zhou G, Myers JN. Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism. Mol Cell Oncol 1(3):e963441, 2014. e-Pub 2014. PMID: 27308343.
- Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics 9(7):1031-46, 2014. e-Pub 2014. PMID: 24786473.
- Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, Skinner HD, Fitzgerald AL, Osman AA, Wei Y, Xia X, Songyang Z, Mills GB, Hung MC, Caulin C, Liang J, Myers JN. Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. Mol Cell 54(6):p960–974, 2014. e-Pub 2014. PMID: 24857548.
- Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand C, Seethala RR, Sano D, Myers JN, Ha PK, Grandis JR, Gaither LA, Puthenveedu MA, Duvvuri U. To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN. Clin Cancer Res 20(17). e-Pub 2014. PMID: 24919570.
- Melancon MP, Zhou M, Zhang R, Xiong C, Allen P, Wen X, Huang Q, Wallace M, Myers JN, Stafford RJ, Liang D, Ellington AD, Li C. Selective Uptake and Imaging of Aptamer- and Antibody-Conjugated Hollow Nanospheres Targeted to Epidermal Growth Factor Receptors Overexpressed in Head and Neck Cancer. ACS Nano 8(5):4530-4538, 2014. e-Pub 2014. PMID: 24754567.
- Gelbard A, Hale KS, Takahashi Y, Davies M, Kupferman ME, El-Naggar AK, Myers JN, Hanna EY. Molecular profiling of sinonasal undifferentiated carcinoma. Head Neck 36(1):15-21, 2014. e-Pub 2014. PMID: 23633104.
- Zhou JH, Kim KB, Myers JN, Fox PS, Ning J, Bassett RL, Hasanein H, Prieto VG. Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Nonpregnant Women, and Men. Am J Dermatopathol 36(1):74-9, 2014. e-Pub 2014. PMID: 23812018.
- Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med 43(1):28-34, 2014. e-Pub 2014. PMID: 23710769.
- Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, Skinner HD. The p53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells. PLoS One 9(8):e104821, 2014. e-Pub 2014. PMID: 25119136.
- Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S. STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. PLoS One 9(1):e81819, 2014. e-Pub 2014. PMID: 24404126.
- Gyanchandani R, Ortega Alves MV, Myers JN, Kim S. A Proangiogenic Signature is Revealed in FGF-Mediated Bevacizumab Resistant Head and Neck Squamous Cell Carcinoma. Mol Cancer Res 11(12):1585-96, 2013. e-Pub 2013. PMID: 24092775.
- Monroe MM, Myers JN, Kupferman ME. Undertreatment of Thick Head and Neck Melanomas: An Age-based Analysis. Ann Surg Oncol 20(13):4362-9, 2013. e-Pub 2013. PMID: 23975303.
- El-Sawy T, Frank SJ, Hanna E, Sniegowski M, Lai SY, Nasser QJ, Myers J, Esmaeli B. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthal Plast Reconstr Surg 29(6):454-7, 2013. e-Pub 2013. PMID: 24195987.
- Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck 35(10):1454-60, 2013. e-Pub 2013. PMID: 23018868.
- Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12(9):1860-73, 2013. e-Pub 2013. PMID: 23839309.
- Wu X, Bhayani MK, Dodge CT, Nicoloso MS, Chen Y, Yan X, Adachi M, Thomas L, Galer CE, Jiffar T, Pickering CR, Kupferman ME, Myers JN, Calin GA, Lai SY. Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget 4(9):1388-98, 2013. e-Pub 2013. PMID: 23963114.
- Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119(16):3034-42, 2013. e-Pub 2013. PMID: 23696076.
- Tan M, Myers JN, Agrawal N. Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am 46(4):545-66, 2013. e-Pub 2013. PMID: 23910469.
- Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional Nodal Recurrence of Sebaceous Carcinoma of the Caruncle 11 Years After Primary Tumor Resection. JAMA Ophthalmol 131(8):1-2, 2013. e-Pub 2013. PMID: 23765335.
- Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, Kim S. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol 49(8):761-70, 2013. e-Pub 2013. PMID: 23623402.
- Hamilton JD, Ahmed S, Sandulache VC, Daram SP, Ow TJ, Skinner HD, Rao A, Ginsberg LE, Kumar AJ, Myers JN. Improving Imaging Diagnosis of Persistent Nodal Metastases after Definitive Therapy for Oropharyngeal Carcinoma: Specific Signs for CT and Best Performance of Combined Criteria. AJNR Am J Neuroradiol 34(8):1637-1642, 2013. e-Pub 2013. PMID: 23471023.
- Myers JN, Sturgis EM. A tale of two cancers: carcinomas of the oral cavity and oropharynx. Otolaryngol Clin North Am 46(4):xiii-xvi, 2013. e-Pub 2013. PMID: 23910479.
- Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3(7):770-81, 2013. e-Pub 2013. PMID: 23619168.
- Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther 12(6):1112-21, 2013. e-Pub 2013. PMID: 23515614.
- Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, Myers JN. Serine Substitution of Proline at Codon 151 of TP53 Confers Gain of Function Activity Leading to Anoikis Resistance and Tumor Progression of Head and Neck Cancer Cells. Laryngoscope 123(6):1416-23, 2013. e-Pub 2013. PMID: 23625637.
- Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar AK, Myers JN. Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck 35(3):321-8, 2013. e-Pub 2013. PMID: 22367702.
- Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 35(3):454-63, 2013. e-Pub 2013. PMID: 22907887.
- Pickering CR, Myers JN. Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discov 3(3):258-9, 2013. e-Pub 2013. PMID: 23475877.
- Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. J Clin Oncol 31(6):744-51, 2013. e-Pub 2013. PMID: 23129742.
- Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med 11(1):198, 2013. e-Pub 2013. PMID: 23981300.
- Ali A, Wang Z, Fu J, Ji L, Liu J, Li L, Wang H, Chen J, Caulin C, Myers JN, Zhang P, Xiao J, Zhang B, Li X. Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells. Nat Commun 4:2667, 2013. e-Pub 2013. PMID: 24157709.
- El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol 130(12):1608-11, 2012. e-Pub 2012. PMID: 23229707.
- Takahashi Y, Kupferman ME, Bell D, Jiffar T, Lee JG, Xie T, Li NW, Zhao M, Frederick MJ, Gelbard A, Myers JN, Hanna EY. Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma. Clin Cancer Res 18(22):6178-87, 2012. e-Pub 2012. PMID: 23032744.
- Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009. e-Pub 2012. PMID: 22950385.
- Sandulache VC, Skinner HD, Wang Y, Chen Y, Dodge CT, Ow TJ, Bankson JA, Myers JN, Lai SY. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther 11(6):1373-80, 2012. e-Pub 2012. PMID: 22572813.
- Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, El-Naggar AK, Ginsberg LE, Rosenthal DI, Glisson BS, Morrison WH, Weber RS, Garden AS. Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 82(3):e367-74, 2012. e-Pub 2012. PMID: 22284033.
- Sano D, Berlin JM, Pham TT, Marcano DC, Valdecanas DR, Zhou G, Milas L, Myers JN, Tour JM. Non-Covalent Assembly of Targeted Carbon Nanovectors Enables Synergistic Drug and Radiation Cancer Therapy In Vivo. ACS Nano 6(3):2497-505, 2012. e-Pub 2012. PMID: 22316245.
- Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM, Wong LJ, Pickering CR, Zhou G, Myers JN. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 118(3):711-21, 2012. e-Pub 2012. PMID: 21720999.
- Sandulache VC, Myers JN. Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets. Head Neck 34(2):282-90, 2012. e-Pub 2012. PMID: 21322078.
- Wang Y, Ow TJ, Myers JN. Pathways for cervical metastasis in malignant neoplasms of the head and neck region. Clin Anat 25(1):54-71, 2012. e-Pub 2012. PMID: 21853469.
- Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18(1):290-300, 2012. e-Pub 2012. PMID: 22090360.
- Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: A meta-analysis. Oral Oncol 48(11):1076-84, 2012. e-Pub 2012. PMID: 22800881.
- Christensen JM, Baumann DP, Myers JN, Buretta K, Sacks JM. Indocyanine green near-infrared laser angiography predicts timing for the division of a forehead flap. Eplasty 12:e41, 2012. e-Pub 2012. PMID: 22977676.
- Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly and initial characterization of a panel of 85 genomically validated cells lines from diverse head and neck tumor sites. Clin Cancer Res 17(23):7248-64, 2011. e-Pub 2011. PMID: 21868764.
- Liu Z, Wei S, Ma H, Zhao M, Myers JN, Weber RS, Sturgis EM, Wei Q. A functional variant at the miR-184 Binding Site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 32(11):1668-74, 2011. e-Pub 2011. PMID: 21934093.
- Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paxlitaxel conjugate inhibits growth of human squamous cell carcinoma of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol 47(11):1039-47, 2011. e-Pub 2011. PMID: 21903450.
- Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C, Myers JN. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 17(21):6658-70, 2011. e-Pub 2011. PMID: 21903770.
- Melancon MP, Lu W, Zhong M, Zhou M, Liang G, Elliott AM, Hazle JD, Myers JN, Li C, Stafford RJ. Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer. Biomaterials 32(30):7600-8, 2011. e-Pub 2011. PMID: 21745689.
- Yom SS, Garden AS, Staerkel GA, Ginsberg LE, Morrison WH, Sturgis EM, Rosenthal DI, Myers JN, Edeiken-Monroe BS. Sonographic examination of the neck after definitive radiotherapy for node-positive oropharyngeal cancer. AJNR Am J Neuroradiol 32(8):1532-8, 2011. e-Pub 2011. PMID: 21757532.
- Berlin JM, Pham TT, Sano D, Mohamedali KA, Marcano DC, Myers JN, Tour JM. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery. ACS Nano 5(8):6643-50, 2011. e-Pub 2011. PMID: 21736358.
- Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117(13):2926-38, 2011. e-Pub 2011. PMID: 21692052.
- Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 30(28):3163-73, 2011. e-Pub 2011. PMID: 21383688.
- Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clinical Nuclear Medicine 36(4):317-9, 2011. e-Pub 2011. PMID: 21368613.
- Ying-Wen S, Tong-xie X, Sano D, Myers JN. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLos One 6(4), 2011. e-Pub 2011. PMID: 21559372.
- Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 21(2):127-30, 2011. e-Pub 2011. PMID: 21169870.
- Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 17(7):1815-27, 2011. e-Pub 2011. PMID: 21350000.
- Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17(8):2281-91, 2011. e-Pub 2011. PMID: 21220477.
- Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, Milas ZL, Morrow PK, Myers JN. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 33(3):349-58, 2011. e-Pub 2011. PMID: 20629091.
- Ow TJ, Myers JN. Current management of advanced resectable oral cavity squamous cell carcinoma. Clin Exp Otorhinolaryngol 4(1):1-10, 2011. e-Pub 2011. PMID: 21461056.
- Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, EFrd P, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178(2):548-71, 2011. e-Pub 2011. PMID: 21281788.
- Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA, Ludwig DL, El-Naggar AK, Weber RS, Myers JN. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 33(2):189-98, 2011. e-Pub 2011. PMID: 20848439.
- Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, Ivan D, Esmaeli B. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg 27(1):e4-6, 2011. e-Pub 2011. PMID: 20940661.
- Agrawal N, Frederick MJ, Pickering CR, Bettegowda C Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Trevino L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidrasky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzer KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154-7, 2011. e-Pub 2011. PMID: 21798897.
- Yilmaz T, Jiffar T, de la Garza G, Lin H, Milas Z, Takahashi Y, Hanna E, MacIntyre T, Brown JL, Myers JN, Kupferman ME. Therapeutic targeting of Trk suppresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther 10(6):644-53, 2010. e-Pub 2010. PMID: 20703101.
- Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S, Fiorentino S, Milas ZL, Kosynkin DV, Price BK, Lucente-Schultz RM, Wen X, Raso MG, Craig SL, Tran HT, Myers JN, Tour JM. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 4(8):4621-36, 2010. e-Pub 2010. PMID: 20681596.
- Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 2010. e-Pub 2010. PMID: 20530716.
- Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/FAR/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 2010. e-Pub 2010. PMID: 20564403.
- Guadagnolo BA, Myers JN, Zagars GK. Role of postoperative irradiation for patients with bilateral cervical nodal metastases from cutaneous melanoma: A critical assessment. Head Neck 32(6):708-13, 2010. e-Pub 2010. PMID: 19787786.
- Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, Myers JN, Bergmann Z, Plinkert PK, Simon C. Development of an oral cancer recurrence mouse model after surgical resection. Int J Oncol 36(4):849-55, 2010. e-Pub 2010. PMID: 20198328.
- Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkB induces EMT and plays a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29(14):2047-59, 2010. e-Pub 2010. PMID: 20101235.
- Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized and malignant oral epithelial cells. Cancer Prev Res (Phila) 3(3):331-8, 2010. e-Pub 2010. PMID: 20145189.
- Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 2010. e-Pub 2010. PMID: 20215556.
- Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: Results of a prospective multi-institutional trial. J Clin Oncol 28(8):1395-400, 2010. e-Pub 2010. PMID: 20142602.
- Mittal MK, Myers JN, Bailey CK, Misra S, Chaudhuri G. Mode of action of the retrogene product SNAI1P, a SNAIL homolog, in human breast cancer cells. Mol Biol Rep 37(3):1221-7, 2010. e-Pub 2010. PMID: 19277896.
- Wang LE, Hu Z, Sturgis EM, Spitz MR, Strom SS, Amos CI, Guo Z, Qiao Y, Gillenwater AM, Myers JN, Clayman GL, Weber RS, El-Naggar AK, Mao L, Lippman SM, Hong WK, Wei Q. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin Cancer Res 16(2):764-74, 2010. e-Pub 2010. PMID: 20068090.
- Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Blasted cell line names. Cancer Inform 9:251-5, 2010. e-Pub 2010. PMID: 21082038.
- Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol 27(28):4727-32, 2009. e-Pub 2009. PMID: 19720915.
- Chakravarty G, Santillan AA, Galer C, Adams HP, El-Naggar AK, Jasser SA, Mohsin S, Mondal D, Clayman GL, Myers JN. Phosphorylated insulin like growth factor-I receptor expression and it's clinico-pathological significance in histologic subtypes of human thyroid cancer. Exp Biol Med (Maywood) 234(4):372-86, 2009. e-Pub 2009. PMID: 19176870.
- Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, Gule M, Zhao M, Zhu Z, Myers JN. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 135(4):411-20, 2009. e-Pub 2009. PMID: 19380367.
- Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 1(1):32, 2009. e-Pub 2009. PMID: 19678942.
- Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, Ju J, Mandal M, Jasser S, Madden T, Myers JN, Priebe W. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8(2):117-27, 2009. e-Pub 2009. PMID: 20192118.
- Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-98, 2008. e-Pub 2008. PMID: 18798304.
- Gelbard A, Kupferman ME, Jasser SA, Chen W, El-Naggar AK, Myers JN, Hanna EY. An orthotopic murine model of sinonasal malignancy. Clin Cancer Res 14(22):7348-57, 2008. e-Pub 2008. PMID: 19010850.
- Hleb EY, Hafner JH, Myers JN, Hanna EY, Rostro BC, Zhdanok SA, Lapotko DO. LANTCET: Elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles. Nanomedicine (Lond) 3(5):647-67, 2008. e-Pub 2008. PMID: 18817468.
- Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 93(10):4088-97, 2008. e-Pub 2008. PMID: 18682509.
- Gomez-Rivera F, Santillan A, McMurphey AB, Paraskevopoulos G, Roberts DB, Prieto VG, Myers JN. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck 30(10):1284-94, 2008. e-Pub 2008. PMID: 18704971.
- Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK, Myers JN. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 14(16):5081-9, 2008. e-Pub 2008. PMID: 18698025.
- Kadara H, Tahara E, Kim HJ, Lotan D, Myers J, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 68(11):4416-23, 2008. e-Pub 2008. PMID: 18519704.
- Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, Sano D, Lin J, Kupferman ME, Santillan AA, Patel V, Gutkind JS, El-Naggar AK, Emberley ED, Watson PH, Matsuzawa SI, Reed JC, Myers JN. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 27(25):3527-38, 2008. e-Pub 2008. PMID: 18223693.
- Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 2008. e-Pub 2008. PMID: 18327819.
- Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J Dent Res 87(1):14-32, 2008. e-Pub 2008. PMID: 18096889.
- Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-84, 2008. e-Pub 2008. PMID: 17989125.
- Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res 67(18):8800-9, 2007. e-Pub 2007.
- Lee TK, Poon RT, Man K, Guan XY, Ma S, Liu XB, Myers JN, Yuen AP. Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett 254(2):308-15, 2007. e-Pub 2007. PMID: 17499430.
- Melancon MP, Wang Y, Wen X, Bankson JA, Stephens LC, Jasser S, Gelovani JG, Myers JN, Li C. Developing of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Investigative Radiology 42(8), 2007. e-Pub 2007. PMID: 17620940.
- Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN. A tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 1(13 (15Pt 1)):4519-27, 2007. e-Pub 2007. PMID: 17671138.
- Ren X, Xu Z, Myers JN, Wu X. Bypass NFkappaB-mediated survival pathways by TRAIL ans Smac. Cancer Biol Ther 7(6):1023-27, 2007. e-Pub 2007.
- Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6(6):1785-92, 2007. e-Pub 2007. PMID: 17575107.
- Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, Kakehata S, Yagihashi S, Shinkawa H. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci 98(6):890-9, 2007. e-Pub 2007. PMID: 17428261.
- Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99:949-61, 2007. e-Pub 2007. PMID: 17565155.
- Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. Oral Oncol 43(5):440-54, 2007. e-Pub 2007. PMID: 16978912.
- Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, Myers JN. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117(4):674-9, 2007. e-Pub 2007. PMID: 17429874.
- Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, Chaturvedi MM, Aggarwal BB. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 26(10):1385-97, 2007. e-Pub 2007. PMID: 16953224.
- Younes MN, Yigitbasi OG, Yazici YD, Jasser SA, Bucana CD, El-Naggar AK, Mills GB, Myers JN. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 133(1):15-23, 2007. e-Pub 2007. PMID: 17224516.
- Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK. Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12:7353-8, 2006. e-Pub 2006. PMID: 17189407.
- Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5:2696-705, 2006. e-Pub 2006. PMID: 17121916.
- Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers JN, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24:4163-9, 2006. e-Pub 2006. PMID: 16943532.
- Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-65, 2006. e-Pub 2006. PMID: 16899627.
- Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res 12:3425-34, 2006. e-Pub 2006. PMID: 16740767.
- Kim S, Yazici YD, Barber SE, Jasser SA, Mandal M, Bekele BN, Myers JN. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck 28:389-99, 2006. e-Pub 2006. PMID: 16388530.
- Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119(6):1268-75, 2006. e-Pub 2006. PMID: 16642480.
- Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 42(4):430-9, 2006. e-Pub 2006. PMID: 16442835.
- Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM, Jr, Myers JN. Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol 263:313-8, 2006. e-Pub 2006. PMID: 16328403.
- Kupferman M, Myers JN. Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol Clin North Am 39:229-47, 2006. e-Pub 2006. PMID: 16580909.
- Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12(2):600-7, 2006. e-Pub 2006. PMID: 16428506.
- Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12:653-61, 2006. e-Pub 2006. PMID: 16428512.
- Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64:106-13, 2006. e-Pub 2006. PMID: 16182463.
- Temam S, Janot F, Germain M, Julieron M, Bretagne E, Myers JN, Marandas P, Mamelle G, Leridant AM, Kolb F, Luboinski B. Functional results with advanced hypopharyngeal carcinoma treated with circular near-total pharyngolaryngectomy and jejunal free-flap repair. Head Neck 28:8-14, 2006. e-Pub 2006. PMID: 16155913.
- Yazici YD, Kim S, Jasser SA, Wang Z, Carter KB, Jr, Bucana CD, Myers JN. Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 115:2249-55, 2005. e-Pub 2005. PMID: 16369175.
- Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 2005. e-Pub 2005. PMID: 16245318.
- Yao M, Roebuck JC, Holsinger FC, Myers JN. Elective neck dissection during salvage laryngectomy. Am J Otolaryngol 26:388-92, 2005. e-Pub 2005. PMID: 16275407.
- Schiff BA, Roberts DB, El-Naggar A, Garden AS, Myers JN. Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg 131:874-8, 2005. e-Pub 2005. PMID: 16230589.
- Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272-86, 2005. e-Pub 2005. PMID: 16145048.
- Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM, Jr, Sturgis EM, Morrison WH, Gershenwald JE, Ross MI, Weber RS, Ang KK. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. Head Neck 27:718-21, 2005. e-Pub 2005. PMID: 15952196.
- Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4:1146-56, 2005. e-Pub 2005. PMID: 16093430.
- Maruya S, Kies MS, Williams M, Myers JN, Weber RS, Batsakis JG, El-Naggar AK. Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol 36:821-7, 2005. e-Pub 2005. PMID: 16084953.
- Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 65:5696-702, 2005. e-Pub 2005. PMID: 15994944.
- Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK. ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion!. Oral Oncol 41:580-8, 2005. e-Pub 2005. PMID: 15975520.
- Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res 65:4716-27, 2005. e-Pub 2005. PMID: 15930290.
- Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92:1899-905, 2005. e-Pub 2005. PMID: 15870708.
- Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4:632-40, 2005. e-Pub 2005. PMID: 15827337.
- Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, Bucana CD, Bekele BN, Myers JN. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11:1963-73, 2005. e-Pub 2005. PMID: 15756022.
- Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN, Myers JN. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 11:1713-21, 2005. e-Pub 2005. PMID: 15755992.
- Yan C, Jamaluddin MS, Aggarwal B, Myers JN, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 4:233-41, 2005. e-Pub 2005. PMID: 15713895.
- Baker H, Patel V, Molinolo AA, Shillitoe EJ, Ensley JF, Yoo GH, Meneses-Garcia A, Myers JN, El-Naggar AK, Gutkind JS, Hancock WS. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral Oncol 41:183-99, 2005. e-Pub 2005. PMID: 15695121.
- Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-602, 2004. e-Pub 2004. PMID: 15623643.
- Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol 40:1026-32, 2004. e-Pub 2004. PMID: 15509494.
- Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, Bekele BN, Fidler IJ, Myers JN. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64:7977-84, 2004. e-Pub 2004. PMID: 15520205.
- Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111:679-92, 2004. e-Pub 2004. PMID: 15252836.
- Garden AS, Asper JA, Morrison WH, Schechter NR, Glisson BS, Kies MS, Myers JN, Ang KK. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?. Cancer 100(6):1171-8, 2004. e-Pub 2004. PMID: 15022283.
- Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM, Jr, Gershenwald JE, Morrison WH, Lee JE, Oswald MJ, Ross MI, Ang KK. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 100(2):383-9, 2004. e-Pub 2004. PMID: 14716775.
- Younes MN, Myers JN. Melanoma of the head and neck: Current concepts in staging, diagnosis, and management. Surg Oncol Clin N Am 13:201-29, 2004. e-Pub 2004.
- Prabhu SS, Diaz E, Sturgis EM, Myers JN, Suki D, DeMonte F. Section on tumors: Mahaley clinical research award: Primary sarcomas of the skull base: an analysis of 63 cases. Clin Neurosurg 51:340-2, 2004. e-Pub 2004. PMID: 15571164.
- Esmaeli B, Ahmadi MA, Youssef A, Diba R, Amato M, Myers JN, Kies M, El-Naggar A. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg 20:22-6, 2004. e-Pub 2004. PMID: 14752305.
- Swan EA, Jasser SA, Holsinger FC, Doan D, Bucana C, Myers JN. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39:648-55, 2003. e-Pub 2003. PMID: 12907203.
- Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9:3183-9, 2003. e-Pub 2003. PMID: 12912971.
- Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 129:864-8, 2003. e-Pub 2003. PMID: 12925346.
- Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 98(3):508-15, 2003. e-Pub 2003. PMID: 12879467.
- Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang K. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97(7):1789-96, 2003. e-Pub 2003. PMID: 12655537.
- Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, Myers JN. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 97(6):1464-70, 2003. e-Pub 2003. PMID: 12627511.
- Lewin JS, Gillenwater AM, Garrett JD, Bishop-Leone JK, Nguyen DD, Callender DL, Ayers GD, Myers JN. Characterization of laryngopharyngeal reflux in patients with premalignant or early carcinomas of the larynx. Cancer 97(4):1010-4, 2003. e-Pub 2003. PMID: 12569600.
- Myers JN, Holsinger FC, Bekele BN, Li E, Jasser SA, Killion JJ, Fidler IJ. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch Otolaryngol Head Neck Surg 128(8):875-9, 2002. e-Pub 2002. PMID: 12162763.
- Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers JN, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322-30, 2002. e-Pub 2002. PMID: 12124833.
- Holsinger FC, Owens JM, Raymond AK, Myers JN. Central mucoepidermoid carcinoma of the mandible: tumorigenesis within a keratocyst. Arch Otolaryngol Head Neck Surg 128(6):718-20, 2002. e-Pub 2002. PMID: 12049571.
- Eicher SA, Clayman GL, Myers JN, Gillenwater AM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 128(3):241-6, 2002. e-Pub 2002. PMID: 11886337.
- Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers JN, Goepfert H, Lotan R, Hong WK, Lipman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. Journal of Clinical Oncology 20(2):364-70, 2002. e-Pub 2002.
- Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 8(1):293-8, 2002. e-Pub 2002. PMID: 11801572.
- Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 92(12):3030-6, 2001. e-Pub 2001. PMID: 11753980.
- Beaver ME, Matheny KE, Roberts DB, Myers JN. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg 125(6):645-8, 2001. e-Pub 2001. PMID: 11743469.
- Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92(9):2364-73, 2001. e-Pub 2001. PMID: 11745292.
- Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers JN, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19(12):3010-7, 2001. e-Pub 2001. PMID: 11408495.
- Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers JN, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7(5):1204-13, 2001. e-Pub 2001. PMID: 11350885.
- Spring PM, Myers JN, El-Naggar AK, Langstein HN. Malignant melanoma arising within a burn scar-case report and review of the literature. Ann Otol Rhinol Laryngol 110(4):369-76, 2001. e-Pub 2001. PMID: 11307915.
- Esmaeli B, Medeiros LJ, Myers JN, Champlin R, Singh S, Ginsberg L. Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation. Arch Ophthalmol 119(3):443-6, 2001. e-Pub 2001. PMID: 11231781.
- Zinner RG, Nemunaitis JJ, Donato NJ, Shin HC, Myers JN, Zhang PS, Zentgraft RE, Lee JJ, Khuri FR, Glisson BS, Eiseman I, Olson SC, Bycott P, Lenehan PF, Hong WK, Shin DM. A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors. Clin Cancer Res 7(11):566, 2001. e-Pub 2001.
- Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60(2):110-5, 2001. e-Pub 2001. PMID: 11244324.
- Myers JN, Elkins T, Roberts D, Byers RM. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 122(1):44-51, 2000. e-Pub 2000. PMID: 10629481.
- Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125(10):1083-9, 1999. e-Pub 1999. PMID: 10522499.
- El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers JN, Luna MA, Benedict WF. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 30(9):1013-8, 1999. e-Pub 1999. PMID: 10492034.
- Jin YT, Myers JN, Tsai ST, Goepfert H, Batsakis JG, el-Naggar AK. Genetic alterations in oral squamous cell carcinoma of young adults. Oral Oncol 35(3):251-6, 1999. e-Pub 1999. PMID: 10621844.
- Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59(8):1820-4, 1999. e-Pub 1999. PMID: 10213484.
- Beaver ME, Myers JN, Griffenberg L, Waugh K. Percutaneous fluoroscopic gastrostomy tube placement in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 124(10):1141-4, 1998. e-Pub 1998. PMID: 9776193.
- Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124(6):641-6, 1998. e-Pub 1998. PMID: 9639473.
- Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 108(2):261-8, 1998. e-Pub 1998. PMID: 9473079.
- Aydogan LB, Myers JN, Myers EN, Kirkwood J. Malignant melanoma metastatic to the tonsil. Laryngoscope 106(3 Pt 1):313-6, 1996. e-Pub 1996. PMID: 8614195.
- Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2(1):127-35, 1996. e-Pub 1996. PMID: 9816099.
- Myers JN, Peel RL, Myers EN. Pathologic quiz case 1. Malignant lymphoepithelial lesion of the parotid gland. Arch Otolaryngol Head Neck Surg 121(4):479-82, 1995. e-Pub 1995. PMID: 7702826.
- Weissman JL, Myers JN, Kapadia SB. Extramedullary plasmacytoma of the larynx. Am J Otolaryngol 14(2):128-31, 1993. e-Pub 1993. PMID: 8484478.
- LeVea CM, Myers JN, Dougall WC, Qian X, Greene MI. A structural and kinetic comparison of proto-oncogenic and oncogenic neu holo-receptors expressed in insect cells. Receptor 3(4):293-309, 1993. e-Pub 1993. PMID: 7908242.
- Mikami Y, Davis JG, Dobashi K, Dougall WC, Myers JN, Brown VI, Greene MI. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Proc Natl Acad Sci U S A 89(16):7335-9, 1992. e-Pub 1992. PMID: 1354355.
- Myers JN, LeVea CM, Smith JE, Kallen RG, Tung L, Greene MI. Expression, purification, and characterization of Bacneu. A soluble protein tyrosine kinase domain encoded by the neu-oncogene. Receptor 2(1):1-16, 1992. e-Pub 1992. PMID: 1362129.
- Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM, Greene MI. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 5(4):489-95, 1990. e-Pub 1990. PMID: 1970151.
- Williams WV, Moss DA, Kieber-Emmons T, Cohen JA, Myers JN, Weiner DB, Greene MI. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A 86(14):5537-41, 1989. e-Pub 1989. PMID: 2501789.
- Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58(2):287-92, 1989. e-Pub 1989. PMID: 2568888.
- Williams WV, Guy HR, Rubin DH, Robey F, Myers JN, Kieber-Emmons T, Weiner DB, Greene MI. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A 85(17):6488-92, 1988. e-Pub 1988. PMID: 2457914.
- Kokai Y, Dobashi K, Weiner DB, Myers JN, Nowell PC, Greene MI. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Proc Natl Acad Sci U S A 85(15):5389-93, 1988. e-Pub 1988. PMID: 2899889.
Invited Articles
- Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Hong CS, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Yin QM, Wang LZ, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Zhuang Z, Lee JJ, Myers JN, Zhang ZY. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget 6(21):18707-14, 2015. e-Pub 2015. PMID: 26124084.
- Duvvuri U, Myers JN. Contemporary Management of Oropharyngeal Cancer. Current Problems in Surgery 46(2):119-184, 2009. e-Pub 2009.
- Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, Clayman GL, Evans DB. Recent advances in thyroid cancer. Curr Probl Surg 45(3):156-250, 2008. e-Pub 2008. PMID: 18346477.
- Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26(3-4):645-62, 2007. e-Pub 2007.
- Harari PM, Cohen RB, Raben D, Myers JN, Vokes EE, Weber RS, Ang KK. The 2007 inaugural ASTRO/ASCO/AHNS multidisciplinary head and neck cancer symposium. Int J Radiat Oncol Biol Phys 69:(2 Suppl):S1-3, 2007. e-Pub 2007. PMID: 17848271.
- Myers JN, Gonzalez HE. Surgery of melanoma of the head and neck. Operative Techniques in General Surgery 6:124-131, 2004. e-Pub 2004.
- Kies MS, Lewin JS, Laccourreye O, Myers JN. Preservation of the Larynx: What are the current standards of care? . Amer Soc Clin Onc 1092-9118(04):331-336, 2004. e-Pub 2004.
- Younes MN, Myers JN. Melanoma of the head and neck: current concepts in staging, diagnosis, and management. Surg Oncol Clin N Am 13(1):201-29, 2004. e-Pub 2004. PMID: 15062370.
- Ferlito A, Rinaldo A, Devaney KO, MacLennan K, Myers JN, Petruzzelli GJ, Shaha AR, Genden EM, Johnson JT, de Carvalho MB, Myers EN. Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol 38(8):747-51, 2002. e-Pub 2002. PMID: 12570052.
- Chen AY, Myers JN. Cancer of the oral cavity. Dis Mon 47(7):275-361, 2001. e-Pub 2001. PMID: 11477373.
- Lentsch EJ, Myers JN. Melanoma of the head and neck: current concepts in diagnosis and management. Laryngoscope 111(7):1209-22, 2001. e-Pub 2001. PMID: 11568543.
- Lentsch EJ, Myers JN. New trends in the etiology, diagnosis, and management of laryngeal dysplasia. Current Opinion Otolaryngology Head Neck Surgery 9:74-78, 2001. e-Pub 2001.
- Chen AY, Myers JN. Cancer of the oral cavity. Curr Probl Surg 37(10):633-731, 2000. e-Pub 2000. PMID: 11055204.
- Myers JN. An update on imaging and management of the N0 neck in patients with upper aerodigestive tract (UADT) cancers. Proceedings on Head and Neck Cancer 5:379-387, 2000. e-Pub 2000.
- Myers JN. The use of biological therapy in cancer of the head and neck. Curr Probl Cancer 23(3):106-34, 1999. e-Pub 1999. PMID: 10397386.
- Myers JN. Value of neck dissection in the treatment of patients with intermediate-thickness cutaneous malignant melanoma of the head and neck. Arch Otolaryngol Head Neck Surg 125(1):110-5, 1999. e-Pub 1999. PMID: 9932599.
- Myers JN. The use of biological therapy in cancer of the head and neck. Advances in Otolaryngology Head Neck Surgery 12:133-163, 1998. e-Pub 1998.
- Myers JN, Goepfert H. Multidisciplinary head and neck cancer care. Current Opinion Otolaryngology Head Neck Surgery 5:93-98, 1997. e-Pub 1997.
- Myers JN, Drebin JA, Wada T, Greene MI. Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu. Methods Enzymol 198:277-90, 1991. e-Pub 1991. PMID: 1677444.
- Myers JN, Kokai Y, Cohen JA, Greene MI. Monoclonal antibodies to oncogene encoded proteins. Immunologic modulation of cell growth, differentiation, and function. Year Immunol 5:178-94, 1989. e-Pub 1989. PMID: 2652927.
Review Articles
- Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer 25(8):613-633, 2025. e-Pub 2025. PMID: 40461793.
- Contrera KJ, Reddy PD, Helou V, Myers JN, Skinner HD, Ferrarotto R, Myers EN. The Evolution of Multidisciplinary Head and Neck Cancer Treatment. Laryngoscope 135(7):2255-2260, 2025. e-Pub 2025. PMID: 39960134.
- Na’ara, S, Andrews, C, Sikora, AG, Williams, MD, Chambers, MS, Myers, JN, Amit, M. Oral Pre-malignancy. Current oncology reports 26(9):1047-1056, 2024. e-Pub 2024. PMID: 38865005.
- Srivastava A, Nogueras-Gonzalez GM, Geng Y, Singh J, Myers JN, Li Y, Chambers MS. Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials. J Immunother Precis Oncol 7(1):24-40, 2024. e-Pub 2024. PMID: 38327757.
- Srivastava, A, Nogueras Gonzalez, G, Geng, Y, Won, AM, Myers, JN, Li, Y, Chambers, MS. Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents. Journal of Immunotherapy and Precision Oncology 4(4):196-207, 2021. e-Pub 2021. PMID: 35665023.
- Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29(5):2305-2317, 2021. e-Pub 2021. PMID: 33190182.
- Chi WJ, Myers JN, Frank SJ, Aponte-Wesson RA, Otun AO, Nogueras-González GM, Li Y, Geng Y, Chambers MS. The effects of zinc on radiation-induced dysgeusia: a systematic review and meta-analysis. Support Care Cancer 28(12):1-12, 2020. e-Pub 2020. PMID: 32642950.
- Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 77(6):1250-1260, 2017. e-Pub 2017. PMID: 28254861.
- Chinn SB, Myers JN. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol 33(29):3269-76, 2015. e-Pub 2015. PMID: 26351335.
- Zhou JH, Sahin AA, Myers JN. Biobanking in Genomic Medicine. Arch Pathol Lab Med 139(6):812-8, 2015. e-Pub 2015. PMID: 26030251.
- Ow TJ, Sandulache VC, Skinner HD, Myers JN. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Cancer 119(22):3914-28, 2013. e-Pub 2013. PMID: 24037788.
- Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30(6):800-9, 2008. e-Pub 2008. PMID: 18429007.
- Werner JA, Dunne AA, Myers JN. Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. Head Neck 25:322-32, 2003. e-Pub 2003. PMID: 12658737.
Editorials
- Oh, SH, Woo, JK, Yazici, YD, Myers, JN, Kim, WY, Jin, Q, Hong, SS, Park, HJ, Suh, YG, Kim, KW, Hong, WK, Lee, HY. Editor’s Note on Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin. Journal of the National Cancer Institute 115(5):602, 2023. PMID: 37011628.
Abstracts
- Zhou JH, Kim KB, Fox P, Myers JN, Prieto VG. Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Non-pregnant Women and Men: a Comparison Study. The United States and Canadian Academy of Pathology 102nd Annual Meeting, 2013. e-Pub 2013.
- Gadhikar MA, Sciuto MR, Alves Ortega MV, Pickering CR, Monroe M, Osman AA, Neskey DM, Sturgis EM, Myers JN, Frederick MJ. Overcoming the Cisplatin Resistance of HNSCC Cells through Chk1/2 Inhibition. Poster Presentation at the 2013 American Association for Cancer Research, 2013. e-Pub 2013.
- Osman AA, Alves MO, Neskey DM, Monroe MM, Patel AA, Chuang H, Mason L, Meyn RE, Byers LA, Katsonis P, Lichtarge O, Myers JN. MK-1775, A Selective wee1 Kinase Inhibitor, Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Squamous Cell Carcinoma of the Head and Neck. American Association of Cancer Research Annual Meeting, 2013. e-Pub 2013.
- Lee J, Kang J, Boo H, Myers JN, Johnson FM, Glisson BS, Oh S, Lee H. Angiogenic Activity Leads Failure of Antitumor Activity of Cixutumumab, an Anti-Insulin Like Growth Factor Receptor Monoclonal Antibody. Poster Presentation at the 2013 American Association for Cancer Research, 2013. e-Pub 2013.
- Takahashi Y, Bell D, Hanna EY, Myers JN, Kupferman ME. Her2/neu as A New Therapeutic Target of Sinonasal Undifferentiated Carcinoma. 23rd Annual North American Skull Base Society Meeting, 2013. e-Pub 2013.
- Nicholas C, Nunez MI, Harun N, Lee JJ, Myers JN, Wistuba II, Sen B, El-Naggar AK, Lai SY, Johnson FM, William WN. SOCS2 (Suppressor of Cytokine Signaling Protein 2) is a Prognostic Indicator of Progression-Free Survival in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients. Poster Presentation at the 2013 American Association for Cancer Research, 2013. e-Pub 2013.
- Fitzgerald AL, Osman AA, Neskey DM, Patel A, Skinner H, McDonnell T, Myers JN. Reactive Oxygen Species and p21Waf1/Cip1 are Essential for Radiation-Induced Accelerated Senescence of Head and Neck Cancer Cells. Poster Presentation at the 2013 American Association for Cancer Research, 2013. e-Pub 2013.
- Y-W S, T-X X, Frederick MJ, Daisuke S, Myers JN. IL-6 stimulates cell motility in squamous cell carcinoma of head and neck (SCCHN) cells through CK2 phosphorylation and stabilization of TWIST. Abstract presented at the AACR Meeting in Washington, DC, April 2010, 2010. e-Pub 2010.
- Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Papadimitrakopoulou V, Heymach J, Raju U, Milas L, Myers JN. Treatment with vandetanib can overcome resistance of head and neck squamous cell carcinoma cells to cisplatin and radiation in an orthotopic animal model. Abstract presented at the AACR Meeting in Washington, DC - April 2010, 2010. e-Pub 2010.
- Gule M, Sano D, Milas Z, Zaho M, Jasser SA, Myers JN. ZD6474 causes significant inhibition of anaplastic thyroid cancer in an orthotopic murine model. Final Program and Abstract Book of the 7th International Conference on Head and Neck Cancer, 2008. e-Pub 2008.
- Zhou G, Myers JN. Reciprocal Negative Regulation Between S100A7/psoriasin and ss-Catenin Signaling in SCCOC Tumor Progression. Final Program and Abstract Book of the 7th International Conference on Head and Neck Cancer, 2008. e-Pub 2008.
- Milas Z, Lucente-Schultz R, Sano D, Galer C, Gule M, Leonard AD, Price BK, Kosynkin D, Tour J, Myers JN. Single-walled carbon nanotubes associated with paxlitaxel inhibit the growth of head and neck squamous cell tumors. Final Program and Abstract Book of the 7th International Conference on Head and Neck Cancer, 2008. e-Pub 2008.
- Sano D, Choi S, Milas ZL, Zhou G, Zhao M, Su YW, Chad G, Maria G, Jasser SA, Myers JN. The effect of combined EGFR and VEGFR-2 targeted therapy, on orthotopic xenografts of SCCOT. Final Program and Abstract Book of the 7th International Conference on Head and Neck Cancer, 2008. e-Pub 2008.
- Zhou G, Zhao M, Xie T, Jasser SA, Myers JN. Gain of function of p53 mutations disrupt the ATM-mediated DNA damage response in HNSCC cell lines. Final Program and Abstract Book of the 7th International Conference on Head and Neck Cancer, 2008. e-Pub 2008.
- Younes MN, Zhou G, Jasser SA, Myers JN. In vivo Imaging of Primary Recurrence and Cervical Lymph Node Metastases in an Orothotopic Nude Mouse Model of Squamous Cell Carcinoma of the head and Neck. Poster presentation at the Combined Otolaryngological Spring Meeting, San Diego, CA, 2007. e-Pub 2007.
- Zhou G, Mandal M, Jasser SA, Zhao M, Yazici YD, Xie T, Younes MN, Kupferman ME, Patel V, Gutkind SJ, El-Naggar AK, Emberley ED, Watson PH, Bucana CD, Myers JN. Psoriasin/S100A7 Modulates b-catenin Signaling and Inhibits Tumor Growth and Progression of Oral Cavity Squamous Cell Carcinoma. Poster presentation at the 97th Annual American Association for Cancer Research Meeting in Los Angeles, CA, 2007. e-Pub 2007.
- Gomez-Rivera F, Santillan-Gomez AA, Gallagher KK, Fooshee D, Zhao M, Jasser SA, Myers JN. AZD2171 in Combination with Paclitaxel is an Effective Therapy for Oral Cavity Squamous Cell Carcinoma in a Murine Orthotopic Model, 2007. e-Pub 2007.
- Ballo MT, Ross MI, Cormier JN, Myers JN, Gershenwald JE, Lee JE, Zagars GK. Combined modality therapy for patients with nodal metastases from melanoma:In press, 2005. e-Pub 2005.
- Kim S, Sreevidya CS, Ananthaswamy HN, El-Naggar AK, Jasser SA, Myers JN. The prevalence of BRAFV599E mutation in anaplastic thyroid carcinoma. 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL. Poster presentation, 2004. e-Pub 2004.
- Yigitbasi OG, Younes MN, Schiff, BA, Doan D, Jasser SA, Al-Muhtaseb Z, Myers JN. Dual inhibition of EGFR and VEGFR in squamous cell carcinoma of the head and neck: the role of the new EGFR/VEGFR inhibitor NVP-AEE788. American Association for Cancer Research, Boston, MA, 2003. e-Pub 2003.
- Kim S, Schiff BA, Doan DD, Younes MN, Jasser SA, Yigitbasi OG, et al. The Effective of NVP AEE788 – A Dual Inhibitor of EGFR and VEGFR Tyrosine Kinase on Anaplastic Thyroid Carcinoma Growth. AACR-NCI-EORTC International Conference on “Molecular Targets and Cancer Therapeutics”, Boston, MA. Poster presentation, 2003. e-Pub 2003.
- Younes M, Swan EA, Doan DD, Myers JN. Inhibition of integrin linked kinase restores anoikis to squamous cell carcinoma of the head and neck cancer cells. American Association for Cancer Research, Washington, D.C, 2003. e-Pub 2003.
- Schiff B, Jasser S, Doan D, Yeung S-C J, Myers JN. An orthotopic nude mouse model of thyroid cancer. American Association for Cancer Research, Washington, D.C, 2003. e-Pub 2003.
- Simon C, Robert D, Rosenthal DI, Diaz EM, Goepfert H, Myers JN. Selective neck dissection is sufficient for persistent neck disease after radiation therapy for advanced stage oropharynx squamous carcinoma. Nashville, TN, 2003. e-Pub 2003.
- Myers JN. Integrin linked kinase (ILK) is overexpressed and ILK inhibition leads to growth inhibition of anaplastic thyroid cancer cells. Nashville, TN, 2003. e-Pub 2003.
- Ballo MT, Zagars GK, Lee JE, Myers JN, Diaz EM, Sturgis EM, Gershenwald JE, Ross MI, Weber RS. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?, 2003. e-Pub 2003.
- Greenburg JS, El-Naggar AK, Mo V, Roberts D, Myers JN. Pathologic and clinical nodal staging discrepancy in oral tongue cancer: Implications for therapeutic decision making. Washington, D.C, 2002. e-Pub 2002.
- Myers JN. PI3-K/AKT signaling in oral cancer progression. Washington, DC, 2002. e-Pub 2002.
- Ginsberg LE, Schomer DF, Gombos DS, Myers JN. Extensive perineural tumor spread in AMLT lymphoma: A mini-tutorial in trigeminal anatomy. Final Program and Abstract Book of the American Society of Neuroradiology, Vancouver, Canada, 2002. e-Pub 2002.
- McDonald TD, Myers JN, Roberts DB, Byers RM. Influence of biopsy type on the prognosis of cutaneous malignant melanoma (CM) of head and neck: A follow-up study. Final Program and Abstract Book of the 5th International Conference on Head and Neck Cancer:148, 2000. e-Pub 2000.
- Holsinger FC, Byers RM, Ahmed SS, Roberts DB, Wolf PF, Myers JN. Clinicopathologic predictors of distant metastases from head and neck squamous cell carcinoma. Final Program and Abstract Book of the 5th International Conference on Head and Neck Cancer:96, 2000. e-Pub 2000.
- Myers JN, Gershenwald JE, Ross MI, Lee JE, Mansfield P. Cutaneous melanoma (CM) arising from non-head and neck primary sites with sentinel lymph nodes (SLN) in the neck. Final Program and Abstract Book of the 5th International Conference on Head and Neck Cancer:329, 2000. e-Pub 2000.
- Myers JN, Li QC, Holsinger FC, Oborn CJ, Jasser S, Killion JJ, Fidler IJ. Therapy of squamous cell carcinoma of the oral cavity (SCCOC) with PK1166, a novel epidermal growth factor receptor (EGF-R) inhibitor. Final Program and Abstract Book of the 5th International Conference on Head and Neck Cancer:104, 2000. e-Pub 2000.
Book Chapters
- Viola, GM, Chambers, MS, Hanasono, MM, Myers, JN. Infectious Complications of Osteoradionecrosis After Head and Neck Cancer Therapy. In: Infections of the Ears, nose, Throat, and Sinuses. 2nd. Springer, 453-467, 2024.
- Myers JN, Kies ME. Chemotherapy and Targeted Biologic Agents for Head and Neck Squamous Cell Carcinoma. In: Cummings Otolaryngology: Head & Neck Surgery. 6. Elsevier, Inc, 2014.
- Monroe MM, Myers JN. Targeted Therapy in Head and Neck Squamous Cell Carcinoma. In: Targeted Therapy in Translational Cancer Research. Wiley, 2014.
- Pickering CR, Ow TJ, Myers JN. Sequencing HNC: Emergence of Notch Signaling. In: Molecular Determinants of Head and Neck Cancer. Springer Science+Business Media, 2014.
- Berger AJ, Myers JN, Nemechek AJ, Yao M. Malignant Melanoma of the Head and Neck Region. In: Bailey's Head and Neck Surgery: Otolaryngology. 5. Lippincott Williams & Wilkins, 2013.
- Myers JN. Posterolateral Neck Dissection. In: Master Techniques in Otolaryngology - Head and Neck Surgery: Head and Neck Surgery: Volume 2: Thyroid, Parathyroid, Salivary Glands, Paranasal Sinuses and Nasopharynx. 1. Lippincott Williams & Wilkins, 67-72, 2013.
- Andrews G, Myers JN. Head and Neck Melanoma. In: Head and Neck Cancer: Multimodality Management. 1. Springer Verlag, 2011.
- Milas Z, Myers JN, Caulin C. Animal Models of Oral Cancer Metastasis. In: Oral cancer metastasis. Springer, 135-162, 2010.
- Galer CE, MyersJN. Angiogenesis and metastases in head and neck cancer. In: Head and Neck Cancer : A Multidisciplinary Approach. 3. Lipppincott Williams & Wilkins, 2009.
- Prabhu SS, Diaz E, Sturgis EM, Myers JN, Suki D, DeMonte F. Primary sarcomas of the skull base: An analysis of 63 cases. In: Clinical Neurosurgery, 2004.
- Younes MN, Myers JN. Melanoma of the head and neck: Current concepts in staging, diagnosis, and management. In: Surgical Oncology Clinics of North America; Current Diagnosis and Therapy for Head and Neck Malignancies, 2003.
- Holsinger FC, Myers JN. Carcinoma of the oral cavity and pharynx. In: Essentials of Otolaryngology and Neck Surgery. 8, 567-595, 2003.
- Sturgis EM, Myers JN. Soft tissue sarcomas of the head and neck in soft tissue sarcomas. In: Unknown. BC Decker, Inc, 2002.
- Nemechek A, Myers JN. Malignant melanoma. In: Head & Neck Surgery-Otolaryngology. Lippincott Williams & Wilkins, 2001.
- Sturgis EM, Myers JN. Nasopharyngeal cancer. In: Decision-Making in ENT Disorders. WB Saunders Company, 2001.
- Myers JN. Metastases of squamous cell carcinoma of the oral tongue. In: Metastases in Head and Neck Cancer, 2001.
- Nemechek AJ, Myers JN. Malignant melanoma. In: Decision-Making in ENT Disorders. W. B. Saunders Co, 2001.
- Lentsch EJ, Myers JN. Melanoma of the head and neck region. In: Melanoma. Springer-Verlag, In press, 2000.
- Lentsch EJ, Myers JN. Melanoma of the head and neck. In: Cancer of the Head and Neck. WB Saunders and Co, 2000.
- Lentsch EJ, Myers JN. Pathogenesis and progression of squamous cell carcinoma of the head and neck. In: Cancer of the Head and Neck, 2000.
- Callender DL, Myers JN. Head and neck cancer. In: Plastic Surgery Secrets. Hanley & Belfus, Inc, 175-185, 1999.
- Myers JN, Myers EN. Carcinoma of the anterior tongue. In: Current Therapy in Otolaryngology in Head and Neck Surgery. Mosby Year Book, 262, 1998.
- Myers JN, Myers EN. Cirugia conservadora para o cancer glotico. In: Cancer Da Laringe. Revinter, 165, 1997.
- Myers JN, Barnes LE, Myers EN. Benign neoplasms of the larynx in fried MP. In: The Larynx: A Multidisciplinary Approach. Mosby Year Book, 1996.
- Myers JN, Whiteside TL. Immunotherapy of head and neck cancer. In: Cancer of the Head and Neck. W.B. Saunders, 805, 1996.
- Myers JN. Molecular pathogenesis of head and neck cancer. In: Cancer of the Head and Neck. W.B. Saunders, 5, 1995.
- Myers JN, Myers EN. Tracheotomy: Indications, technique potential complications. In: Tratado de Otorrinolaryngologia Editora Roca LTDA, 1994.
- Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI. The role of the neu oncogene product in cell transformation and normal development. In: Princess Takamatsu Symp. Immune System and Cancer. Japan Sci Soc Press, 45-57, 1988.
Books (edited and written)
- Editors Myers JN Hanna EY, Myers EN. Cancer of the Head and Neck. Ed(s) 5th. Wolters Kluwer, 2017.
- Myers JN, Sturgis EM. Oral cavity and oropharyngeal cancer. Elsevier, 2013.
- Myers JN. Oral cancer metastasis. Springer, 2010.
- Myers JN. Cancer of the head and neck. Ed(s) 4. Saunders, 2003.
- Myers JN. The role of sentinel lymph node mapping and biopsy in cutaneous melanomas of the head and neck region, 2001.
Letters to the Editor
- Myers JN, Goepfert H. Regional lymph nodes and melanomas. Arch Otolaryngol Head Neck Surg 124: 826, 1998.
- Myers JN. Adjuvant immunotherapy for patients with melanoma. Head Neck 20: 270, 1998.
Patient Reviews
CV information above last modified March 11, 2026